Canadian clinical practice guidelines for invasive candidiasis in adults

Co-Chairs (listed alphabetically): Eric J Bow MD MSc D Bacteriol FRCPC, Gerald Evans MD FRCPC, Jeff Fuller PhD FCCM DIAABMM, Michel Laverdière MD, Coleman Rotstein MD FRCPC FACCP; Principal Authors (listed alphabetically): Robert Rennie PhD FCCM DIAABMM, Stephen D Shafran MD FRCPC FACCP, Don Sheppard MD FRCPC; Co-Authors (listed alphabetically): Sylvie Carle BPharm MSc, Peter Phillips MD FRCPC, Donald C Vinh MD FRCPC FACP

Candidemia and invasive candidiasis (C/IC) are life-threatening opportunistic infections that add excess morbidity, mortality and cost to the management of patients with a range of potentially curable underlying conditions. The Association of Medical Microbiology and Infectious Disease Canada developed evidence-based guidelines for the approach to the diagnosis and management of these infections in the ever-increasing population of at-risk adult patients in the health care system. Over the past few years, a new and broader understanding of the epidemiology and pathogenesis of C/IC has emerged and has been coupled with the availability of new antifungal agents and defined strategies for targeting groups at risk including, but not limited to, acute leukemia patients, hematopoietic stem cell transplants and solid organ transplants, and critical care unit patients. Accordingly, these guidelines have focused on patients at risk for C/IC, and on approaches of prevention, early therapy for suspected but unproven infection, and targeted therapy for probable and proven infection.

Key Words: Adults; Candidiasis; Epidemiology; Guidelines; Prophylaxis; Therapy

EXECUTIVE SUMMARY

Candidemia and invasive candidiasis (C/IC) are infections affecting an ever-increasing number of hospitalized patients. C/IC causes considerable morbidity and mortality in patients with medical comorbidities who possess risk factors for these infections such as broad-spectrum antibacterial therapy, intense myelosuppression and cytotoxic therapies, recent gastrointestinal surgery and the presence of central venous access devices. A variety of Candida species may produce C/IC, but Candida albicans continues to be the most common inciting pathogen. The present document, prepared by the Association of Medical Microbiology and Infectious Disease (AMMI) Canada with the assistance of practitioners from Pharmacy and Hematology-Oncology, attempts to provide an evidence-based guideline for the diagnosis and management of C/IC in adult patients. The guidelines were prepared with other similar endeavours in mind (1-13), and are for consideration by critical care physicians, internal medicine specialists, and pharmacists.

La septicémie à Candida et la candidose envahissante (SC/CE) sont des infections opportunistes au potentiel fatal qui ajoutent une morbidité, une mortalité et des coûts excessifs à la prise en charge des patients atteints d'une série de troubles sous-jacents pouvant être guéris. L'Association pour la microbiologie médicale et l'infectiologie Canada a préparé des directives probantes sur les méthodes diagnostiques et thérapeutiques de ces infections dans la population toujours croissante de patients adultes vulnérables au sein du système de santé. Depuis quelques années, on constate de nouvelles connaissances et une meilleure compréhension de l'épidémiologie et de la pathogénie de la SC/CE, couplées à la mise en marché de nouveaux antifongiques et de stratégies définies pour cibler les groupes vulnérables, y compris, sans s'y limiter, les patients atteints d'une leucémie aiguë, les greffés de cellules souches hématopoïétiques et d'organes pleins et les patients aux soins intensifs. Par conséquent, ces directives portent sur les patients vulnérables à la SC/CE et sur les démarches de prévention, le traitement précoce d'une infection présumée mais non démontrée et une thérapie ciblée en vue de souigner une infection probable et prouvée.
pharmacists, infectious diseases physicians, clinical and medical microbiologists, surgical specialists, hematologists and medical oncologists.

These guidelines cover the epidemiology, pathogenesis and immunobiology, microbiology and resistance issues, diagnosis, infection prevention and control concepts, and therapy of C/IC. Recommendations based on existing evidence and expert opinion for the risk stratification of the severity of illness are provided to guide diagnosis and therapy of C/IC in both non-neutropenic and neutropenic hosts. Furthermore, the principles of therapeutic approaches to C/IC involving prophylaxis, pre-emptive, empirical and specific therapy for documented infection are reviewed in the present guidelines. A grading system was used to rate recommendations according to strength (A to C) and the quality of evidence (I to III). The following is a summary of the recommendations:

Prevention of C/IC in leukemic and hematopoietic stem cell transplant recipients
1. For acute leukemia patients undergoing primary or secondary remission induction therapy, in which the duration of severe neutropenia is expected to be longer than 10 days, oral fluconazole 400 mg daily may be administered from the time of initiation of induction chemotherapy until myeloid reconstitution (A-I). The intravenous (IV) formulation may be substituted during periods of intolerance due to oral mucositis (B-I). Alternatively, oral itraconazole 200 mg twice daily (B-I) or posaconazole 200 mg three times daily initiated 24 h after completion of chemotherapy (such as vinca alkaloids, taxanes or anthracyclines) (A-I), or IV caspofungin 50 mg daily may be considered (B-III).
2. For allogeneic hematopoietic stem cell transplant (HSCT) recipients, oral fluconazole 400 mg daily is recommended for use from the beginning of conditioning until at least 75 days post-transplant (A-I). The IV formulation may be substituted during periods of intolerance due to oral mucositis (B-I). Alternatively, itraconazole oral solution 200 mg twice daily (B-I), posaconazole 200 mg three times daily initiated 24 h after completion of chemotherapy (A-I), or IV micafungin 50 mg daily may be considered (B-III).
3. Antifungal prophylaxis with fluconazole among postremission consolidation patients is not recommended (B-II).
4. Antifungal prophylaxis with fluconazole for autologous HSCT recipients, particularly those receiving concomitant hematopoietic growth factor support, is not recommended (B-II).

Prevention of C/IC in solid organ transplant recipients
5. Hepatic transplantation
   i. Data are insufficient to support routine fungal cultures of the donor duodenal fluid (C-III); and
   ii. To support anastomotic healing, fluconazole 400 mg/day for four weeks post-transplant may be recommended (B-III). Alternative antifungal agents for this purpose may include lipid formulations of amphotericin B, extended-spectrum azoles or echinocandins (B-III).
6. Pancreatic transplantation
   i. Data are insufficient to support routine fungal cultures of the donor duodenal fluid (C-III); and
   ii. To support anastomotic healing, fluconazole 400 mg/day for four weeks post-transplant may be recommended (B-III).
7. Small bowel transplantation
   i. In centres where C albicans is prevalent, fluconazole 400 mg/day for four weeks post-transplant may be recommended (B-III). In centres where Candida glabrata and Candida krusei are potentially more prevalent, a lipid formulation of amphotericin B 3 mg/kg/day to 5 mg/kg/day may be substituted (B-III).
8. Renal transplantation
   i. Data are insufficient to support a recommendation for routine antifungal prophylaxis (C-III).
9. Lung and heart/lung transplantation
   i. Specific recommendations for anti-Candida prophylaxis cannot be made in isolation. The risks for invasive aspergillosis must be considered when deciding on prophylaxis.
10. Cardiac transplantation
    i. Specific recommendations for anti-Candida prophylaxis cannot be made in isolation. The risks for invasive aspergillosis must be considered.

Prevention of C/IC in intensive care unit patients
11. Routine antifungal prophylaxis of all intensive care unit (ICU) patients is not recommended (B-III). However, antifungal prophylaxis aimed at Candida species using fluconazole in selected high-risk subgroups of ICU patients may significantly decrease the likelihood of developing proven C/IC and reduce all-cause mortality (A-I).
12. High-risk subgroups of patients who may be candidates for prophylaxis include the following:
   i. ICU patients with recurrent gastrointestinal perforation or anastomotic leakage. In this selected high-risk group, IV fluconazole 400 once daily may be administered until either complete resolution of intra-abdominal disease, development of proven Candida species infection requiring directed antifungal therapy or development of a severe drug-related adverse event (A-I); and
   ii. Patients admitted to a tertiary referral centre ICU (surgical or medical) with a baseline risk for C/IC of 10% or greater if there is an anticipated stay of more than three days. In such cases, oral fluconazole 400 mg daily may be administered until ICU discharge, until initiation of directed antifungal therapy for suspected/confirmed disease or development of a severe drug-related adverse event (A-I); and
   iii. There are insufficient data to support specific recommendations for antifungal prophylaxis in severe acute pancreatitis (SAP) (C-III).

Treatment of C/IC in neutropenic patients and HSCT recipients
13. Pre-emptive use of antifungal agents for C/IC in neutropenic patients, based on the presence of colonization and/or...
surrogate serological markers for C/IC, is impractical and not recommended (C-III).

14. Empirical antifungal therapy is recommended for patients with a persistent or recrudescence neutropenic fever syndrome after four to seven days of broad-spectrum antibacterial therapy without a focus of infection for suspected C/IC or other possible invasive fungal infections (IFIs) (B-I).

15. Therapeutic choices for empirical antifungal therapy in febrile neutropenic cancer patients and HSCT recipients with a persistent neutropenic fever syndrome or recrudescence neutropenic fever syndrome include the following: a lipid formulation of IV amphotericin B at a dose of 3 mg/kg/day (A-I), IV caspofungin 70 mg as a loading dose and then IV 50 mg daily (A-I), IV amphotericin B deoxycholate 0.6 mg/kg/day to 1.0 mg/kg/day (B-II in the absence of risk factors for nephrotoxicity, otherwise the deoxycholate formulation of amphotericin B is not recommended), fluconazole for those less critically ill patients with neutropenia of short duration (seven days or fewer) and in the absence of azole prophylaxis with IV fluconazole 800 mg as a loading dose and then IV 400 mg daily with the option of proceeding to oral doses of 400 mg daily (B-II), and IV voriconazole 6 mg/kg every 12 h for 24 h and then IV 4 mg/kg every 12 h or oral doses of 200 mg twice daily (based on the risk of mould infection in these patients) (B-I).

16. The duration of empirical antifungal therapy is until resolution of symptoms and signs of infection, including fever, in conjunction with the recovery of the absolute neutrophil count (ANC) to 0.5×10^9/L or greater for at least 48 h (A-I).

17. For microbiologically or histologically documented (proven) C/IC in neutropenic patients and HSCT recipients, IV amphotericin B deoxycholate 0.6 mg/kg/day to 1.0 mg/kg/day (in the absence of risk factors for nephrotoxicity), a lipid formulation of IV amphotericin B 3 mg/kg/day, and IV caspofungin 70 mg as a loading dose and then IV 50 mg daily are all recommended (A-I). IV anidulafungin 200 mg initially followed by IV 100 mg daily or IV micafungin 100 mg daily may also be effective (B-III). Fluconazole 800 mg followed by IV/oral doses of 400 mg doses may be used in hemodynamically stable, less severely ill patients with neutropenia of shorter duration (seven days or fewer) (A-II). The choice of agent will depend on local epidemiology, use of azole antifungal prophylaxis and concerns regarding coexistent mould infection.

18. If Candida parapsilosis C/IC is present and caspofungin, anidulafungin or micafungin have been used, another agent of a different class (amphotericin B deoxycholate, lipid formulation of amphotericin B or fluconazole for less critically ill patients with a shorter duration of neutropenia) may be considered, if the patient is not responding or improving. However, if the patient has improved on echinocandin therapy, then it may be continued (B-III). For hemodynamically unstable neutropenic patients and HSCT recipients with proven C. parapsilosis C/IC, amphotericin B deoxycholate or a lipid formulation of amphotericin B is preferred (B-III).

19. Removal of venous access devices is recommended for candidemia in neutropenic cancer patients and HSCT recipients (whether catheter related or not) provided that this procedure is feasible (B-II).

20. The duration of therapy for microbiologically documented C/IC in neutropenic patients is at least two weeks after the clearance of organisms from the bloodstream and/or the infected body site, with resolution of all signs and symptoms at the infected site and recovery of the ANC to greater than 0.5×10^9/L for at least 48 h (A-I).

**Treatment of C/IC in non-neutropenic patients**

21. Pre-emptive antifungal therapy in non-neutropenic patients with the presence of colonization is currently not recommended (C-III).

22. Empirical antifungal therapy may be beneficial in critically ill patients who meet specific criteria based on clinical prediction rules for C/IC (B-II). Fluconazole remains efficacious in reducing C/IC and is cost effective at a loading dose of 800 mg followed by IV 400 mg daily for hemodynamically stable patients (B-II). However, empirical antifungal therapy may not produce resolution of fevers of unknown origin in non-neutropenic ICU patients and is weakly endorsed (C-II). In hemodynamically unstable patients, an echinocandin (anidulafungin 200 mg initially followed by IV 100 mg daily, caspofungin 70 mg initially followed by IV 50 mg daily or IV micafungin 100 mg daily) may be preferred for empirical therapy (C-III).

23. The duration of empirical therapy in non-neutropenic patients should be 14 days (B-II).

24. For microbiologically or histologically documented (proven) C/IC in hemodynamically stable patients with no previous azole exposure in the past 30 days, fluconazole 800 mg initially followed by IV 400 mg daily, or an echinocandin (anidulafungin 200 mg as a loading dose followed by IV 100 mg daily, caspofungin 70 mg as a loading dose followed by IV 50 mg daily or IV micafungin 100 mg daily) are recommended (A-I).

25. IV amphotericin B deoxycholate at a dose of 0.5 mg/kg/day to 1 mg/kg/day (in the absence of risk factors for nephrotoxicity) or lipid formulations of IV amphotericin B at a dose of 3 mg/kg/day are alternatives (B-I).

26. For proven C/IC caused by C. glabrata in hemodynamically stable patients, in centres where susceptibility testing is available, fluconazole should only be used if the isolate is susceptible. However, if fluconazole is initiated at the outset but susceptibilities are not available and the patient is clinically improved, it may be continued (B-III).

27. For hemodynamically stable or unstable patients with proven C/IC caused by C. parapsilosis, fluconazole is preferred (B-II). In hemodynamically unstable patients, lipid formulations of amphotericin B or amphotericin B deoxycholate are alternatives for therapy for C/IC (C-II).

28. In hemodynamically unstable patients with proven C/IC due to Candida species other than C. parapsilosis with or without azole exposure, an echinocandin (anidulafungin 200 mg followed by IV 100 mg daily, caspofungin 70 mg initially followed by IV 50 mg daily or IV micafungin 100 mg daily) is preferred (B-III).

**METHOD**

The authors’ working group was comprised of specialists with expertise in hematology, infectious diseases, clinical and medical
Invasive candidiasis treatment guidelines

TABLE 1
Infectious Disease Society of America – United States public health service grading system for rating recommendations in clinical guidelines

<table>
<thead>
<tr>
<th>Category, grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>Good evidence to support a recommendation for or against use</td>
</tr>
<tr>
<td>B</td>
<td>Moderate evidence to support a recommendation for or against use</td>
</tr>
<tr>
<td>C</td>
<td>Poor evidence to support a recommendation</td>
</tr>
</tbody>
</table>

Quality of evidence

| I               | Evidence from ≥1 properly randomized, controlled trial |
| II              | Evidence from ≥1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from >1 centre); from multiple time-series or from dramatic results from uncontrolled experiments |
| III             | Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees |

Adapted from reference 14

TABLE 2
Incidence of candidemia in various populations

<table>
<thead>
<tr>
<th>Years of observation</th>
<th>Country</th>
<th>Rate (per 100,000 population)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999–2004</td>
<td>Canada</td>
<td>2.9</td>
<td>21</td>
</tr>
<tr>
<td>1998–2001</td>
<td>USA</td>
<td>6.0</td>
<td>36</td>
</tr>
<tr>
<td>1998–2000</td>
<td>USA</td>
<td>10.0</td>
<td>53</td>
</tr>
<tr>
<td>2003–2004</td>
<td>Denmark</td>
<td>11.0</td>
<td>24</td>
</tr>
<tr>
<td>1995–1999</td>
<td>Iceland</td>
<td>4.9</td>
<td>27</td>
</tr>
<tr>
<td>1995–1999</td>
<td>Finland</td>
<td>1.9</td>
<td>37</td>
</tr>
<tr>
<td>2002–2003</td>
<td>Spain</td>
<td>4.3</td>
<td>22</td>
</tr>
<tr>
<td>1991–2003</td>
<td>Norway</td>
<td>2.4</td>
<td>38</td>
</tr>
<tr>
<td>2001–2004</td>
<td>Australia</td>
<td>1.8</td>
<td>51</td>
</tr>
</tbody>
</table>

microbiology, oncology, pharmacy and transplant medicine and were selected based on member expertise by the co-chairs of the AMMI Canada Guidelines Committee. A Medline literature review of more than 600 articles, published between 2000 and 2009 in the English language literature, was accomplished using a combination of more than 40 key words pertaining to invasive candidiasis. Sections of the document were assigned to individual primary and co-author pairs, with sections being merged into a single draft document that was circulated twice to all authors for initial and final review. A grading system for rating clinical practice guidelines was used to categorize the recommendations according to strength (A to C) and quality of evidence (I to III) (Table 1) (14). Consensus on the recommendations contained in the document was obtained using the Delphi process (15).

All members of the working group complied with the AMMI policy on conflicts of interest that require disclosure of any financial or other interests that might be construed as constituting an actual, potential or apparent conflict. Members of the working group were provided a conflicts of interest disclosure statement and were asked to identify any affiliations or financial interests with pharmaceutical companies that might potentially affect the guideline. Information was requested regarding ownership of stock or stock options, employment or paid consultancy within the past two years, honoraria, speaker fees, educational grants and travel assistance to attend meetings. Potential conflicts are identified at the end of the present document.

EPIDEMIOLOGY AND RISK FACTORS

Candida species cause a wide spectrum of diseases. These range from the frequent superficial infections of mucosal surfaces, skin or nail infections, to the less-common life-threatening invasive infections. By definition, invasive candidiasis refers to infection in deep-seated tissue or other normally sterile sites, excluding the urine, documented by histopathology and/or microbiological culture. The current epidemiology of invasive candidiasis is almost exclusively based on Candida bloodstream infection (BSI) studies (16-25). Surveillance studies (26-30) have shown that Candida species are responsible for up to 10% of all documented BSIs. Large variations exist among countries, as shown in Table 2, which illustrates the incidence of candidemia identified from surveillance studies conducted in general populations. Reviews (19) have reported similar incidences in hospital populations. Variations reflect the differences in the populations surveyed including their geographical situation and the nature of their illnesses. The highest rates are observed in the very young and elderly patient populations (31).

A large database of nosocomial BSIs in the United States has ranked Candida species fourth overall among nosocomial BSIs, and the third most common cause of such infections in the ICU (32). Similar findings were reported in a survey (33) of ICUs in the Calgary Health Region, Alberta. Between May 2000 and April 2003, Candida species accounted for 10% of BSIs, equivalent to Enterococcus faecium as the fifth most common pathogen. However, reports (26,34,35) from European hospitals have shown lower rates of Candida species BSI (sixth to eighth most common cause of nosocomial infections). It is generally perceived that the incidence of C/IC continues to rise; data from several surveillance studies (24,32,36-39) have shown a continued rise into the 21st century. By contrast, other studies (26,40-43) have reported either stability or a reduction in their observed incidence of C/IC. The use of different denominators and results derived from specific critically ill populations may explain those discrepant observations. The repeated use of the same statistics to support the rising incidence of invasive Candida species infections has likely masked the true regional and global incidences. Only comparisons of carefully collected standardized data at discrete time points will establish the true variations between centres, regions and countries.

There are clear geographical differences in the distribution of Candida species causing BSIs. C albicans is the most commonly reported species (Table 3). In most countries, it is followed by C glabrata except in Latin America and Australia, where C parapsilosis is more prevalent. The emergence of C glabrata and C parapsilosis as the second/third most common Candida species causing BSIs was mainly recognized during the past 20 years and is strongly associated with patient comorbidity state and patient type. C glabrata tends to affect patients with hematological malignancies and solid tumours or older patients, while C parapsilosis is more likely to be associated with intravascular catheter-related BSIs and is more predominant in neonatal units (36,44-46). It has been suggested by some
authors that the increased use of fluconazole for antifungal prophylaxis and treatment may have favoured the emergence of C. glabrata, while other studies failed to establish a similar relationship (47-49).

The common underlying medical conditions and risk factors predisposing patients to invasive Candida infections are indicated in Table 4. An important continuum exists between the conditions and the risk factors. To predisposed medical conditions, such as cancer, prematurity, advanced age and acute renal failure, added risk factors such as broad-spectrum antibacterial therapy, intense myelosuppressive and cytotoxic therapies for hematological malignancies or solid tumors, recent gastrointestinal surgery, treatments in ICUs and use of central venous catheterization are among the factors that increase the risk and incidence of C/IC (25,30,43,45,46,50-53). Some factors may, however, be surrogate markers of the burden of the underlying illness and in-hospital treatment conditions, rather than specific factors for infection. Many of these factors are less likely to be involved in the emerging observation of patients who develop candidemia infections outside of the hospital. In a recent, large, population-based surveillance study (54), 28% of patients with candidemia had disease onset outside of the hospital. These infections occur in patients with extensive contact with the health care system, and likely reflect the increasing number of patients with complex medical conditions that are treated on an outpatient basis. A high index of suspicion is necessary to reduce the morbidity and mortality in these patients.

The burden of Candida BSIs has been recently examined. Candidemia is still associated with high crude (35% to 61%) and attributable (24% to 49%) mortality rates, and significant economic burden (55-59). Different studies have attributed most of the economic burden to either an increase in hospitalization or to the cost of the antifungal treatments and their attributable (24% to 49%) mortality rates, and significant economic burden (55-59). Different studies have attributed most of the economic burden to either an increase in hospitalization or to the cost of the antifungal treatments and their associated toxicities. In a recent analysis (60) of the economic impact of candidemia in Canada, the total average hospital and treatment charges were approximately $70,000.

**TABLE 3**

**Candida bloodstream infections: Distribution of species reported in publications from 2000 to 2006**

<table>
<thead>
<tr>
<th>Location</th>
<th>Studies, n</th>
<th>Isolates, n (range)</th>
<th>C albicans</th>
<th>C glabrata</th>
<th>C tropicalis</th>
<th>C parapsilosis</th>
<th>C krusei</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>5</td>
<td>6130</td>
<td>55</td>
<td>20</td>
<td>11</td>
<td>11</td>
<td>2</td>
<td>36,43,53,380,381</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(254–2759)</td>
<td>(45–59)</td>
<td>(12–24)</td>
<td>(9–12)</td>
<td>(7–14)</td>
<td>(1–2)</td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>5</td>
<td>4186</td>
<td>57</td>
<td>14</td>
<td>7</td>
<td>18</td>
<td>2</td>
<td>26,52,381-383</td>
</tr>
<tr>
<td>Scandinavia</td>
<td>3</td>
<td>2201</td>
<td>70</td>
<td>13</td>
<td>4</td>
<td>5</td>
<td>3</td>
<td>37,38,383</td>
</tr>
<tr>
<td>Canada</td>
<td>3</td>
<td>1114</td>
<td>62</td>
<td>15</td>
<td>6</td>
<td>11</td>
<td>3</td>
<td>374,384,385</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(208–464)</td>
<td>(54–64)</td>
<td>(11–17)</td>
<td>(4–9)</td>
<td>(9–12)</td>
<td>(3)</td>
<td></td>
</tr>
<tr>
<td>Latin America</td>
<td>2</td>
<td>967</td>
<td>40</td>
<td>8</td>
<td>22</td>
<td>23</td>
<td>1</td>
<td>20,383</td>
</tr>
<tr>
<td>Australia</td>
<td>1</td>
<td>1068</td>
<td>47</td>
<td>15</td>
<td>5</td>
<td>20</td>
<td>4</td>
<td>51</td>
</tr>
</tbody>
</table>

**TABLE 4**

**Common conditions and interventions at risk for candidemia/invasive candidiasis**

<table>
<thead>
<tr>
<th>Factors</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>386,387</td>
</tr>
<tr>
<td>Broad-spectrum antibiotic therapy</td>
<td>186,203,386,383,390</td>
</tr>
<tr>
<td>Candida colonization</td>
<td>113,132,134,252,339</td>
</tr>
<tr>
<td>Central vascular venous and arterial catheters</td>
<td>216,273,388,391</td>
</tr>
<tr>
<td>Diabetes</td>
<td>176</td>
</tr>
<tr>
<td>Extensive surgery or burns</td>
<td>388,392</td>
</tr>
<tr>
<td>Immunosuppressed status</td>
<td>393,394</td>
</tr>
<tr>
<td>Intensive cancer ablative chemotherapy</td>
<td>17,119</td>
</tr>
<tr>
<td>Organ transplantation</td>
<td>99,111</td>
</tr>
<tr>
<td>Prolonged intensive care unit stay</td>
<td>71,380,395,396</td>
</tr>
<tr>
<td>Prolonged neutropenia</td>
<td>109,252,397</td>
</tr>
<tr>
<td>Parenteral nutrition</td>
<td>398</td>
</tr>
<tr>
<td>Renal disease and hemodialysis</td>
<td>70,380,399</td>
</tr>
</tbody>
</table>

**Figure 1** Pathogenesis of candidemia/invasive candidiasis. Blastospores of Candida gain access to the endovascular compartment via gut translocation or endovascular catheter colonization (A). Candida blastospores germinate within the bloodstream and interact with soluble serum components (B) and circulating neutrophils (C). Organisms then adhere to and penetrate vascular endothelial cells (D) to gain access to the deep organs, where they interact with dendritic cells and monocyte macrophages (E) that activate adaptive immune responses (F).
candidiasis occurs when the organism breaches these barriers and gains access to the endovascular compartment. This invasion may result from colonization and growth on an intravascular catheter, or by translocation across gut mucosa. Translocation across the intestinal mucosa can be enhanced by intestinal fungal overgrowth induced by broad-spectrum antibiotics and the presence of epithelial injury induced by surgery or cytotoxic chemotherapy. However, such injury is not absolutely required, as demonstrated by Krause et al (61) when both candiduria and candidemia resulted from the ingestion of a massive quantity of C. albicans (10^12 organisms) by a healthy individual. Thus, the density of organisms facilitates translocation.

After breaching the first line of defense and entering the endovascular compartment, Candida species interact with multiple arms of the host defense system including both immune cells and soluble factors. The innate immune response comprises the majority of these responses and a clearer picture of the various interactions involved in this response is emerging. The majority of these studies have been performed using C. albicans, which will, therefore, be the focus of the discussion. It is important to note, however, that it is clear that not all Candida species have the same virulence factors, and further studies with non-albicans species are required.

On entry into the bloodstream, blastospores of C. albicans interact with a number of soluble factors (Figure 1). Mannose-binding lectin avidly binds cell wall mannose ligands and activates the lectin-dependent pathway of complement, although no clear role for protection against infection has been identified for this molecule (62,63). Both the classical and alternative complement pathways are also activated by Candida blastospores, and C3b fragments have been found to bind directly to the cell wall of C. albicans (64,65). This activation of the complement cascade results in opsonization and improves phagocytosis of Candida blastospores in vitro. Also, the alternative complement pathway is important for the host defense against disseminated candidiasis in experimental animal models of infection (66). While anti-Candida antibodies are often present in serum, their protective role during natural infection remains unclear (67).

Candida also interacts with multiple cellular elements of the innate immune system. Recognition of Candida by host cells is a critical element of this response and is transduced by multiple pattern recognition receptors (PRRs) that recognize candidal pathogen-associated molecular patterns (PAMPs) such as chitin, mannan and glucan. Stimulation of these receptors stimulates dendritic cells and macrophages to produce inflammatory cytokines with multiple effects including the recruitment and activation of neutrophils as well as polarization of T cell regulatory responses. Toll-like receptors (TLRs) – TLR-2 and TLR-4 – expressed on the surface of monocyte/macrophages and dendritic cells are the best studied of these PRRs in disseminated candidiasis. TLR-4 recognizes Candida mannan, and mediates the production of a variety of proinflammatory cytokines and chemokines including interleukin (IL)-8 and macrophage-inflammatory protein 2, which are associated with protection against Candida infection (68). Candida phospholipomannan and β-glucan are recognized by TLR-2, resulting in the production of prostaglandin E2 and the cytokine IL-10, which suppresses effective immune responses and is associated with poor prognosis during experimental infection (69,70). Manipulation of this balance of immune responses by changes in morphology and cell wall content is one of the key mechanisms whereby C. albicans evades immune responses. While blastospores of C. albicans activate both TLR-2 and TLR-4 responses to induce a protective type 1 response, hyphae of C. albicans are poorly recognized by TLR-4, leading to an increase in IL-10 production and a type 2 immune response, both of which are associated with poor survival (70,71).

In addition to TLRs, other host cell PRRs have been described including the lectins dectin-1 and -2, and dendritic cell-specific intracellular adhesion molecule grabbing nonintegrin (DC-sign) (72-74). These receptors are thought to play an important role in the phagocytosis of nonopsonized C. albicans, and mediation of innate immune responses. Interestingly, while dectin-1 recognizes (1,3)-β-D-glucan in C. albicans blastospores, this recognition is masked in hyphae and may, therefore, also contribute to the impaired type 1 response during disseminated infection and hyphal invasion (74).

Neutrophils provide a key line of defense against disseminated candidiasis (Figure 1). They avidly phagocytose and kill Candida blastospores, and can damage C. albicans hyphae (75). This intracellular killing is dependent on the ability to generate an intact oxidative burst, explaining why patients with chronic granulomatous disease are susceptible to recurrent Candida infections (76-78). Intracellular killing and recruitment are enhanced by the cytokine milieu elaborated by dendritic cells, macrophages and T cells. Other professional phagocytic cells, including eosinophils, monocytes and dendritic cells, are also able to ingest and kill Candida, although to a lesser degree. To combat these host defenses, C. albicans has evolved several virulence strategies. Hyphae of C. albicans elaborate catalase to protect against oxidative killing (79,80). Indeed, genetically engineered strains that are deficient in catalase are hypovirulent in animal models of infection (79).

To enhance survival in the nutrient-poor phagolysosome of the macrophage, C. albicans uses the glyoxylate cycle to use fatty acids and their breakdown products (81).

In addition to professional immune cells, Candida species also interact with another important cell type, the vascular endothelial cells. To develop deep-seated organ infection, organisms must adhere to and transgress the endothelial cell lining of blood vessels (82-84). Endothelial cells are more than a passive bystander in the pathogenesis of invasive candidiasis. Endothelial cells actively endocytose germinating C. albicans, and respond to infection by releasing a variety of proinflammatory mediators including tumour necrosis factor-alpha, monocye chemoattractant protein 1 and IL-8 (85,86). They also respond to C. albicans by increased surface expression of leukocyte adhesion molecules such as E-selectin, intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 (85,86). These interactions are mediated, at least in part, by the agglutinin-like sequence family of C. albicans proteins. These immunoglobulin-like cell wall proteins mediate adherence to a variety of host substrates including endothelial and epithelial cells. In addition, one member of the agglutinin family, Als3, functions as a fungal invasion by binding to endothelial cell N-cadherin (87).

In addition to the virulence mechanisms already outlined, C. albicans produces a number of extracellular hydrolytic...
enzymes thought to play a role in mediating damage to host tissues. A family of secreted aspartyl proteases encompassing 10 members is expressed during infection, and confers increased virulence (82). In addition, secreted phospholipase (88) and lipase (89) have been described and may also play a role in disseminating infection. Finally, the capability to form a biofilm may also adversely affect the clinical outcome of candidemic patients (90).

ANTIFUNGAL AGENTS
Mechanisms of action
Polynes:
Amphotericin B is a large molecular weight polyene agent. It interacts with sterols in the membrane of yeasts and moulds producing aqueous pores and altered membrane permeability, thereby killing the cell (91-94). Amphotericin B is fungicidal and, in some strains of yeast, fungidal activity occurs at the minimal inhibitory concentration; in others, there is delayed killing of the cell (95,96). The significance of prolonged or delayed killing is not understood clinically, but may result in either treatment failure or the necessity of prolonged treatment. The deoxicholate formulation of amphotericin B is associated with nephrotoxicity and infusion-related patient reactions (ie, fever, chills and rigors), and while newer lipid-based formulations exhibit equivalent efficacy, they are also associated with variable toxicity (97).

Azoles:
Fluconazole, itraconazole, posaconazole and voriconazole are all triazole agents that are used frequently in antifungal treatment. Ketoconazole is a diazole that is used for the treatment of mycetomas, but is no longer available in the oral form in Canada. In general, azoles act by inhibiting cytochrome P-450-dependent 14-alpha-demethylation of lanosterol (in the cytoplasm), a fungal sterol that is not present in mammalian cells (98-101). Other more complex interactions may occur (99,101-104), but the result is a depletion of ergosterol, the major membrane sterol that confers cell membrane stability in yeasts and many fungi. Azole antifungals can also inhibit many mammalian cytochrome P-450-dependent enzymes involved in hormone synthesis or drug metabolism. Therefore, azole antifungals are particularly susceptible to clinically significant drug interactions with other medications metabolized through the P450 pathway. Each azole offers a specific antifungal spectrum. Earlier agents in the class demonstrated potent activity against some yeasts, and itraconazole had some activity against moulds including Aspergillus species. The newer, extended-spectrum triazoles, such as voriconazole and posaconazole, have been shown to have fungicidal activity against moulds, as well as enhanced activity against Candida species and other yeasts (105,106).

Echinocandins:
These agents include anidulafungin, caspofungin and micafungin. All are lipopeptides that interfere with (1,3)-β-D-glucan synthase activity – the major enzyme that catalyzes the linkage of glucose molecules in the cell wall to form structurally stable cells. The resulting interaction leads to an unstable fungal cell wall, leakage of cellular contents and eventual disruption of the cell (107,109). The spectrum of activity is, therefore, limited to pathogens that rely on these glucan polymers and is less broad than the spectrum of the polyene or azole agents. As such, the echinocandins primarily have potent activity against species of Candida including C krusei and Aspergillus but not Cryptococcus (110). Because mammalian cells have no cell wall, the echinocandins have very few toxic adverse effects in humans.

5-Fluorocytosine (5-FC or flucytosine): The mechanism of action of this agent is to interfere with pyrimidine metabolism, causing inhibition of both DNA synthesis and protein synthesis in the fungal cell. 5-FC is transported into the fungal cell by a specific permease, converted to the active moiety 5-fluorouracil by a specific enzyme, and is then incorporated into replicating DNA to interfere with cell division (111,112). In the laboratory, 5-FC appears to have reasonable activity against many yeast species including Candida and Cryptococcus. However, in vivo, combination therapy is required with membrane active agents, such as amphotericin B, that may enhance 5-FC diffusion into the cell. The reason for this dichotomy between in vitro and in vivo activity is not well understood. 5-FC is also not recommended for monotherapy due to the high likelihood of inducing de novo resistance during therapy.

Mechanisms of resistance
Microbiological resistance to the polyenes is rare. Although the exact mechanisms are not clear, the outcome at the cellular level is either reorientation of existing ergosterol, or decreased ergosterol content (113,114), ultimately creating a cell that is less responsive to the action of amphotericin B.

Resistance to azoles may result from the modification of the target heme enzymes, either by a change or reduction in the affinity of the drug for the target or by changes in the concentration of the target enzymes (115-117). Alternatively, similar to many bacterial species, yeast and moulds are capable of pumping drugs back out of the cell by active efflux. Two groups of proteins have been described that can effect azole efflux. These are called major facilitator superfamily proteins and ATP-binding cassette superfamily proteins (118-120). The presence of the drug may also result in the overexpression of ergosterol synthesis and overwhelm the antifungal activity of the drug (116).

For the echinocandins, documented resistance occurs infrequently. Resistance arises from genetic mutations in the FKS genes (121). In limited publications, the minimum inhibitory concentrations (MICs) to caspofungin have been shown to rise from 0.25 mg/L to 16 mg/L (122,123), and there are few documented failures to establish the clinical significance of these mutations (124,125). Some cross-resistance has been documented with the other echinocandins, micafungin and anidulafungin (126).

Resistance to 5-FC is more readily observed. It results either from loss of uptake of the agent due to decreased permease activity (required to take the agent into the cell), or loss of the enzymes cytosine deaminase or uracil phosphoribosyltransferase required to convert 5-FC to 5-fluorouracil and transport it to its target site (127,128).

Relevance of resistance
Ideally, susceptibility interpretations for antimicrobial testing are formulated based not only on the MIC distribution within a pathogen population, but also on relevant pharmacokinetic/pharmacodynamic (PK/PD) and clinical outcome evidence for specific disease manifestations. In this fashion, the MIC can reliably predict the likelihood of antimicrobial treatment failure. However, as with antibacterial susceptibility testing,
there is a paucity of PK/PD and clinical outcome data for available antifungal agents that limits the utility of MIC as a clinical correlate, particularly in the context of microbiological resistance.

Azole interpretive breakpoints relevant to C/JIC have been established for fluconazole, itraconazole and voriconazole by the Clinical and Laboratory Standards Institute (CLSI) (129-131). In addition to susceptible (S) and resistant (R) categories, there is also a susceptible dose-dependent (S-DD) category designed to indicate the need for increased serum or tissue levels of azole for Candida isolates with increased MIC values. Fluconazole breakpoints, established in 1997 (130), have been well validated and correlate with clinical outcome, especially for failure with resistant isolates (132). Cross-resistance to fluconazole and voriconazole has been reported in vitro as well as in the clinical setting, notably following prolongedazole exposure (fluconazole, then voriconazole), with C glabrata as the predominant isolate (133-141). This clinical resistance is captured by the new voriconazole breakpoints, in which resistance to fluconazole confers the same interpretation for voriconazole. However, for Candida isolates with a reduced fluconazole MIC (S-DD), voriconazole remains susceptible and a viable treatment option, likely due to voriconazole's increased activity (131). Interpretive breakpoints for intraconazole are not well validated, particularly for the IV (not available in Canada) and oral suspension formulations, which exhibit more reliable serum concentrations. In time, the accumulation of clinical data may improve the utility of itraconazole and facilitate the validation of relevant interpretive breakpoints.

Although C glabrata and C kruesi are typically less susceptible to azoles than C albicans, surveillance data indicates that resistance rates have remained relatively unchanged for more than a decade. Global surveillance of Candida bloodstream and sterile site isolates from 1992 to 2004 indicates that fluconazole resistance (13,338 isolates) is still uncommon for most species (3% or lower), particularly for C albicans (0.06%) (132). C glabrata and C kruesti resistance rates were considerably higher (9% and 40%, respectively) (132). This was not unexpected for C kruesi (intrinsic fluconazole resistance), but there is growing concern that both the prevalence and fluconazole resistance of C glabrata in C/JIC may be increasing (132,140,142,143). Overall resistance to voriconazole (13,338 isolates) and intraconazole (7299 isolates, assumed breakpoint of 1 mg/L or less) was 0.9% and 4%, respectively; C glabrata resistance was 3.7% and 23%, and C kruesi resistance was less than 1% and 6% for voriconazole and intraconazole, respectively (131,144,145).

In vitro susceptibility testing of Candida species against amphotericin B produces a very narrow range of MIC values that precludes the assignment of interpretive breakpoints with any relevance to clinical outcome (146,147). This also prevents accurate surveillance of changes in the MIC distribution profile of Candida species over time. However, isolates with an MIC greater than 1 mg/L are unusual and elevated amphotericin B dosing may be required for therapy, most notably for C glabrata and C kruesi (147-152).

Although the CLSI breakpoints for 5-FC have been accepted, they have not been as rigorously validated with PK/PD and clinical outcome data as other agents (ie, azoles), and it is unlikely that they will ever be used due to the contraindication of 5-FC for monotherapy. However, global surveillance of 8803 invasive Candida isolates (1992 to 2001) found that 5-FC remained highly active (3% resistance or lower) over time, with the exception of C krueri (28% resistance) (137).

An interpretive breakpoint for echinocandin-susceptible Candida has been recently proposed (153), but the clinical correlation of echinocandin in vitro activity for C/JIC, particularly for elevated MIC values, remains unclear. Analysis of more than 100 invasive isolates recovered from patients receiving caspofungin therapy provided no correlation between the caspofungin MIC and clinical outcome (154). This is likely due, in part, to an absence of supporting PK/PD data and isolates with documented echinocandin resistance included in the study. Caspofungin has maintained excellent in vitro activity against Candida species, according to a four-year (2001 to 2004) global surveillance study (155). More than 99% of 8197 invasive isolates had an MIC of 1 mg/L or less, which can be readily achieved in serum from a 1 mg/kg daily dose (155,156). Isolates that had increased MIC values (0.3%) were primarily less-frequent species causing invasive disease including C parapsilosis, Candida guilliermondii, C krueri and Candida lusitaniae (154). In fact, the MIC distributions of these species tend to be 10-fold greater than more clinically prevalent species (ie, C albicans and C glabrata), but still remain 1 mg/L or less, more than 99% of the time (155,157), and seem to respond well to caspofungin therapy (158). Similarly, isolates with known FKS genetic mutations (conferring caspofungin microbiological resistance) may be distinguished from wild type species by MIC values greater than 2 mg/L (157,159).

Pharmacodynamic and pharmacokinetic considerations

The selection of an appropriate agent depends on multiple factors in addition to the spectrum of activity. The routes of administration and elimination are important considerations when selecting the optimal therapy for a patient with an invasive fungal infection. Alterations in gastrointestinal tract integrity, impaired renal or hepatic function, and limited IV access are frequent issues for these patients. Some antifungals are available only as IV preparations (amphotericin B and echinocandins) or only as oral preparations (5-FC, itraconazole and posaconazole). Many antifungals are associated with host toxicities, wide intrapatient and interpatient variability in serum concentrations (voriconazole) and drug interactions (including chemotherapeutic agents) (Table 5). Therefore, it is important to have an appreciation of the differences among these drugs with regard to their pharmacokinetic properties, including absorption (may require a fatty meal or acidification for agents such as intraconazole, posaconazole and voriconazole), distribution (echinocandins do not penetrate the cerebrospinal fluid and should not be used for meningitis therapy), metabolism and excretion. Understanding the relationship among the PK/PD properties of antifungals is essential to optimize the potential for favourable clinical and microbiological outcomes, while minimizing risks of treatment-related toxicity (for further reading, refer to references 110,160-164).

**DIAGNOSIS OF C/JIC**

The early descriptions of C/JIC highlighted the difficulty in establishing a timely diagnosis given the significant proportion
may at least be equivalent. Early identification of C. albicans from blood cultures has been demonstrated with the lysis-centrifugation technique (168), but is labor intensive, not widely available, and newer automated blood culture systems are labor intensive, not widely available, and newer automated blood culture systems are not (169). Improved blood culture methodology has increased the sensitivity from approximately 50% to possibly 70% for C. albicans (167). Improved recovery of microorganisms from blood cultures, rather than waiting for positive blood cultures, has been performed successfully on samples collected directly in situ hybridization techniques (171). Recently, the germ tube test (169) and (1,3)-β-D-glucan test methodology, which detects a panfungal cell wall antigen and is now available in at-risk patient populations (184). The detection of antibodies directed against Candida antigens – including enolase (a glycolytic enzyme) (185,186), mannann (186), a heat labile antigen (Cand-Tec assay) (186) and (1,3)-β-D-glucan (186-191) – has held the greatest potential. However, such assays have generally demonstrated variable diagnostic utility and/or limited availability. The most promising of these is the (1,3)-β-D-glucan test methodology, which detects a panfungal cell wall antigen and is now available in Canada.

TABLE 5
Common drug interactions associated with azole coadministration

<table>
<thead>
<tr>
<th>Azole</th>
<th>Drug action or serum concentration is increased by azole coadministration</th>
<th>Azole action or serum concentration is decreased by drug coadministration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluconazole</td>
<td>Astemizole*, benznidazolamine (eg, midazolam), cisanpride†, cyclosporine, glyburide, glipizide, phenytoin, tacrolimus, terfenadine†, theophylline, warfarin</td>
<td>Rifabutin†, rifampin†</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Benznidazolamine (eg, midazolam)†, carbamazepine†, cisanpride†, cyclosporine, digoxin, ergot alkaloids†, fentanyl†, 3-hydroxy-3-methylglutaryl-coenzyme A (eg, lovastatin)†, barbiturates, pimozone†, quinidine†, rifabutin, sirolimus, tacrolimus</td>
<td>Carbamazepine†, phenytoin, rifabutin†, rifampin†</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>Astemizole*, benznidazolamine (eg, midazolam), cisanpride*, cyclosporine, digoxin, ergot alkaloids†, phenytoin, pimozone†, quinidine†, sirolimus†, tacrolimus†, terfenadine†, warfarin</td>
<td>Carbamazepine†, barbiturates†, phenytoin, rifabutin†, rifampin†</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>Astemizole*, benznidazolamine (eg, midazolam), cisanpride†, cyclosporine, ergot alkaloids†, pimozone†, quinidine†, sirolimus†, terfenadine†</td>
<td>Cicletidine, efavirenz, phenytoin, rifabutin†, rifampin†</td>
</tr>
</tbody>
</table>

*Not available in Canada; †Contraindicated

of cases only diagnosed postmortem (165,166). In a series of 40 surgical patients with disseminated candidiasis published 37 years previously, premortem cultures established the diagnosis in 24 (60%) cases including positive blood cultures in 17 (43%) cases (166). Clinical signs and symptoms are usually nonspecific and cultures may be negative or only positive in advanced disease. Despite efforts to develop a variety of noninvasive assays during the past few decades, there is no widely available, reliable diagnostic technique that represents an improvement over routine culture of sterile body fluids or biopsy specimens in most cases.

Microbiology
Recovery of Candida species from a single specimen of a normally sterile body fluid (except urine) establishes a diagnosis of C/IC (167). Improved blood culture methodology has increased the sensitivity from approximately 50% to possibly 70% for candidemia or disseminated candidiasis. Improved recovery of Candida from blood cultures has been demonstrated with the lysis-centrifugation technique (168), but is labour intensive, not widely available and newer automated blood culture systems may at least be equivalent. Early identification of C. albicans versus non-albicans Candida species may be possible by germ tube formation or rapid screening techniques such as the use of selective and chromogenic media (169,170) or immunofluorescent in situ hybridization techniques (171). Recently, the germ tube test has been performed successfully on samples collected directly from positive blood cultures, rather than waiting for Candida colonies to grow on agar plates (172,173).

Predictive value of colonization
Among surgical patients, Solomkin et al (174) demonstrated colonization at two or more sites in 31 (50%) of 63 patients before the development of candidemia. Leukemic patients with multiple site colonization, single site colonization and no Candida colonization developed candidemia in 22%, 5% and 0% of cases, respectively (175). Due to the difficulty in establishing a diagnosis of invasive candidiasis, clinicians have adopted empirical antifungal therapy (176) in selected patients, particularly those at high risk, with a compatible clinical picture of sepsis and multiple sites of Candida colonization, as well as other risk factors for C/IC as outlined below.

Other laboratory investigations
Peripheral blood leukocytosis is present in up to 50% of patients with C/IC (177). Patients with chronic disseminated candidiasis (hepatosplenic candidiasis) usually have an elevated serum alkaline phosphatase level (167,178,179).

Imaging
Various imaging studies may be helpful in establishing a diagnosis of focal invasive candidiasis. Examples include the urinary tract (eg, ultrasound for ‘fungus balls’), spine (eg, bone scan, computed tomography or magnetic resonance imaging) and heart valves (echocardiogram). Patients with hematological malignancy may develop typical small, peripheral, target-like abscesses (bull’s-eye lesions) in the liver and/or spleen in chronic disseminated candidiasis demonstrated by computed tomography, magnetic resonance imaging or ultrasound (167,178,179).

Investigational methods
Various noninvasive assays have included detection methods for Candida antibodies, antigens, metabolites and nucleic acids (180,181). Detection of antibodies directed against Candida species has not been useful in identifying patients with invasive candidiasis (182). The Candida metabolite D-arabinitol has also proven to be unreliable for this purpose (180). Although polymerase chain reaction assays have the promise of providing sensitivity beyond traditional blood culture methods (180,183), further work will be needed to adapt the methodology to the clinical laboratory and provide adequate validation in at-risk patient populations (184). The detection of Candida antigens – including enolase (a glycolytic enzyme) (185,186), mannann (186), a heat labile antigen (Cand-Tec assay) (186) and (1,3)-β-D-glucan (186-191) – has held the greatest potential. However, such assays have generally demonstrated variable diagnostic utility and/or limited availability. The most promising of these is the (1,3)-β-D-glucan test methodology, which detects a panfungal cell wall antigen and is now available in Canada.

INFECTION PREVENTION AND CONTROL OF C/IC
Hospital-based infection control practices should focus on prevention methods to reduce identified risk factors for nosocomial invasive Candida infections. Effective interventions that are evidence based and designed to prevent these infections require an understanding of the epidemiology including reservoirs of the pathogen, modes of transmission, evidence for clonal spread and the pathophysiology of nosocomial C/IC. Moreover, the morbidity, mortality and costs related to nosocomial C/IC are
intimately linked to the severity of the underlying illness and the associated treatments for that illness (192).

Epidemiology of nosocomial C/IC
Successful preventive strategies are based on identification of the potential reservoir. Different reservoirs require different methods for prevention of transmission and disease. Based on molecular typing, invasive Candida species may be classified as being derived from either the patient’s endogenous microflora or exogenous from another patient by direct or indirect contact (193,194).

The majority of cases of C/IC appear to be endogenous in origin based on experimental murine models (195); the identification of the same Candida genotype from multiple anatomical sites on an individual patient over time, with the density of colonization predictive of subsequent C/IC (196-199); the identical (or very closely related) genotype profile between colonizing and infecting strains and molecular typing studies demonstrating that the colonizing isolate typically precedes the infecting isolate (25,193,194,199-202). This relationship has been demonstrated in neutropenic (200), non-neutropenic (193), critically ill (199,202) and neonatal patients (203). The two major endogenous reservoirs are the gastrointestinal tract and the skin (195), with carriage rates of 40% to 50% reported in healthy persons (19). Alternatively, gastrointestinal candidiasis may be acquired de novo while in hospital, with colonization rates as high as 40% being reported (204). Infection occurs with translocation of Candida species from the gastrointestinal tract into the submucosal tissue and the circulation.

Numerous exogenously acquired nosocomial clusters of C/IC have been reported. Based on molecular typing, the most commonly implicated vehicles of transmission have been from the hands of health care workers (HCWs) (205-213). In addition to the hands of HCWs (214-216), environmental surfaces (217,218), contaminated IV infusates (219-221), medications (222), the hospital environment (223-225), fomites such as blankets and mattresses (226) and hands of family members (227) have also been reported as reservoirs. In some cases, patients may act as the initial nosocomial source, bringing their strain into the hospital, with subsequent transmission to HCWs and to other patients (228-230). Direct patient-to-patient transmission of Candida species has also been described unmediated by HCWs (231).

Preventive measures
Colonization is the essential first step in the pathogenesis of C/IC; accordingly, effective infection control measures should focus on reducing or preventing such exposures.

Endogenous acquisition: It is not clear whether oral ingestion of Candida species in foods or liquids contributes significantly to the risk for C/IC. Only one cluster of invasive C. krusei infections in association with a foodborne source, bottled lemon juice, has been reported in the literature (232). Otherwise, there is a paucity of evidence linking health care facility-derived food sources to outbreaks of C/IC. The prolonged use of broad-spectrum antibacterial agents has been repeatedly identified as a significant risk factor for C/IC (25,194,228,233-237). While direct empirical evidence is lacking, it may be reasonable to expect that rational antimicrobial usage policies, extrapolated from strategies designed to limit nosocomial bacterial resistance (238), may affect the rates of Candida species colonization and infection. The risk for endogenously acquired C/IC can be estimated by examining the degree of colonization of body sites by Candida species. Pittet et al (199) described the colonization index as the ratio between the number of different body sites (other than blood) colonized by Candida and the total number of anatomical sites cultured. The corrected colonization index is estimated from the ratio between the number of different body sites showing heavy growth and the total number of different body sites from which Candida species were isolated, then multiplying this ratio by the colonization index. The derived thresholds to predict risk of C/IC were colonization index greater than 0.5 (positive predictive value 66%; negative predictive value 100%) and corrected colonization index greater than 0.4 (positive predictive value 100%; negative predictive value 100%) (199). The use of surrogate prediction rules based on colonization profiles, as a strategy to trigger or prevent the pre-emptive administration of antifungal agents, is an attractive possibility (239-243), but not routinely practiced (57).

Exogenous acquisition: The high prevalence of hand carriage of Candida species by HCWs and the isolation of identical (or highly related) genotypes among nosocomial clusters provide indirect evidence for HCWs as a significant reservoir for transmission within the hospital (209,212,244,245). Hand hygiene is, therefore, recommended using an antimicrobial soap and water; however, alcohol-based hygienic hand rubs are acceptable alternatives (246). Hand hygiene and adequate nail hygiene may compromise the efficacy of such techniques (216,247,249). Some investigators have implemented additional aggressive infection prevention measures successfully – including cohorting of patients and personnel, barrier precautions (including wearing gowns and gloves on entering patient rooms), minimizing patient transfers to and from their rooms and enforcing hand hygiene among colonized patients – either alone (250) or in conjunction with selected chemoprophylaxis (251).

Central venous catheters may serve as a portal of entry for Candida either by extraluminal skin contamination, by contaminated catheter hubs or by contaminated infusates. Candida species infection accounts for approximately 10% of all vascular catheter-related infections (252). This topic has been recently reviewed (253) and guidelines regarding the prevention (254) and management (255,256) of central venous catheter-related infections have been published.

ANTIFUNGAL MANAGEMENT OF C/IC
C/IC affects disparate patient populations depending on the underlying immune deficiency and extrinsic predisposing risk factors. The populations affected range from neutropenic cancer patients and HSCT recipients to non-neutropenic patients (52,257). As a result, the approach to the treatment of C/IC can be subdivided into two groups of patients: those who are neutropenic versus those who are non-neutropenic. There are four strategies that have evolved for the prevention and treatment of C/IC: prophylactic antifungal therapy to prevent Candida infection in those at high risk; pre-emptive antifungal therapy for patients without evidence of clinical candidiasis, but who are at risk and who may have additional surrogate markers of early infection such as mucosal colonization, circulating antigens, serological markers or circulating genomic material;
**TABLE 6**

Recommendaions for the prophylaxis and treatment of candidemia/invasive candidiasis (C/IC) in neutropenic patients

<table>
<thead>
<tr>
<th>Therapeutic strategy</th>
<th>Preferred</th>
<th>Antifungal therapeutic options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prophylactic therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-risk patients (neutropenia &lt; 7 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute leukemia (remission induction) and allogeneic HSCT</td>
<td>Not recommended (A-III)</td>
<td>NA</td>
</tr>
<tr>
<td>Acute leukemia (postremission consolidation) or HGF-supported autologous HSCT</td>
<td>Not recommended (B-II)</td>
<td>NA</td>
</tr>
<tr>
<td>Pre-emptive therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Empirical therapy</td>
<td>IV LFAmB 3 mg/kg/day (A-I); or caspofungin 70 mg on day 1, then IV 50 mg daily (A-I); or IV AmB-d 0.6 mg/kg/day to 1.0 mg/kg/day (B-II in the absence of risk factors for nephrotoxicity)</td>
<td>Fluconazole 800 mg or IV/oral 400 mg/day (for less severely ill patients [B-II]; or voriconazole 6 mg/kg every 12 h for 24 h, then IV doses of 4 mg/kg every 12 h or oral doses of 200 mg twice daily (if risk of mould infection present) (B-I)</td>
</tr>
<tr>
<td>Therapy for microbiologically or histologically documented C/IC</td>
<td>IV AmB-d 0.6 mg/kg/day to 1.0 mg/kg/day (A-I); or IV LFAmB 3 mg/kg/day (A-I); or IV ECH (IV anidulafungin 200 mg → 100 mg daily [B-III]; or IV caspofungin 70 mg → 50 mg daily [A-I]; or IV micafungin 100 mg daily [B-III])</td>
<td>Fluconazole 800 mg or IV/oral 400 mg/day (for less severely ill patients [A-I]; or IV voriconazole 6 mg/kg every 12 h for 24 h then 4 mg/kg every 12 h or oral doses of 200 mg twice daily (if risk of mould infection is present) (B-I)</td>
</tr>
</tbody>
</table>

AmB-d Amphotericin B deoxycholate; LFAmB Lipid formulation amphotericin B; ECH Echinocandin; HGF Hematopoietic growth factor; HSCT Hematopoietic stem cell transplant; NA Not applicable

empirical antifungal therapy for suspected but unproven C/IC based on the symptom of fever unresponsive to broad-spectrum antibacterial therapy with no other obvious source of infection (258,259); and directed antifungal therapy for the treatment of proven or probable (microbiologically or histologically documented) C/IC infection.

**Prevention of C/IC in leukemic and HSCT recipients**

**Recommendations (Table 6)**

1. For acute leukemia patients undergoing primary or secondary remission-induction therapy in which the duration of severe neutropenia is expected to be longer than 10 days, oral fluconazole at 400 mg daily may be administered from the time of initiation of induction chemotherapy until myeloid reconstitution (A-1). The IV formulation may be substituted during periods of intolerance due to oral mucositis (B-I). Alternatively, itraconazole oral solution 200 mg twice daily (B-I) or posaconazole 200 mg three times daily initiated 24 h after completion of chemotherapy (such as vinca alkaloids, taxanes or anthracyclines) (A-I) or IV caspofungin 50 mg daily may be considered (B-III).

2. For allogeneic HSCT recipients, oral fluconazole 400 mg daily is recommended for use from the beginning of conditioning until at least day 75 post-transplant (A-I). The IV formulation may be substituted during periods of intolerance due to oral mucositis (B-I). Alternatively, itraconazole oral solution 200 mg twice daily (B-I), posaconazole 200 mg three times daily initiated 24 h after completion of chemotherapy (A-I), or IV micafungin 50 mg daily commencing at the time of transplant (B-I) may be considered.

3. Antifungal prophylaxis with fluconazole among postremission consolidation patients is not recommended (B-II).

4. Antifungal prophylaxis with fluconazole for autologous HSCT recipients, particularly those receiving concomitant hematopoietic growth factor support, is not recommended (B-II).

**Summary of evidence**

Effective infection prevention strategies for leukemic and HSCT patients should exert their effects during periods of greatest patient vulnerability (260). Host defense deficits that place patients at risk for IFIs are not constant over time and the pathogenesies of IFIs vary with the pathogens involved. For example, the pathogenesis of C/IC is, for the most part, related to translocation of opportunistic yeasts across cytotoxic therapy-damaged mucosal surfaces colonized by these microorganisms (Figure 1) (261,262). In contrast, opportunistic moulds are transmitted by inhalation of airborne conidia into the upper and lower airways of susceptible hosts. An understanding of these two pathogenic mechanisms is important to the selection of effective strategies for the prevention of pathogen acquisition.

Most HSCT transplant centres in the United States, Japan and Europe report using antifungal chemoprophylaxis (fluconazole 67%; itraconazole 13%; IV amphotericin B 13%) (263-266). The proportional average increase in use of extended-spectrum mould-active azoles between 2001 and 2005 was 192%, suggesting that physicians’ concerns for mould infections increased significantly over this time period.

Fluconazole has been administered in oral doses ranging from 50 mg to 400 mg once daily; however, the weight of evidence suggests that among highest risk patients, the higher dose is more effective (267). A similar observation for the oral solution of itraconazole has been reported (268). The ability to switch from the oral formulation to an IV formulation for the same antifungal product in the setting of severe oral mucositis has been seen as an advantage. The prophylactic use of voriconazole in allogeneic HSCT recipients at oral doses of 200 mg twice daily or IV doses of 200 mg every 12 h has also been considered. In one recently completed but unpublished
trial (269), voriconazole was associated with a significant reduction in the likelihood of invasive aspergillosis compared with fluconazole, yet the fungal infection-free survival was not different. A small, double-blind, placebo-controlled trial (270) of prophylactic voriconazole in acute leukemia patients demonstrated a marked reduction in the incidence of pulmonary infiltrates and hepatosplenic candidiasis. Two large randomized fluconazole- or itraconazole-based controlled clinical trials in acute leukemia patients (271) and in HSCT recipients with acute or chronic graft-versus-host disease (272) have demonstrated the efficacy of oral posaconazole at doses of 200 mg three times daily for reducing invasive mould infections. Prophylactic micafungin (273) and caspofungin (274) at daily IV doses of 50 mg have been shown to have similar anti-Candida treatment effects as fluconazole and itraconazole, respectively.

**Start and stop dates for antifungal prophylaxis for invasive candidiasis**

Prophylaxis should be initiated in parallel with the administration of cytotoxic therapy (263,267) to ensure a protective effect at the time of maximal neutropenia and intestinal epithelial damage. Triazole-related drug interactions with antibiotics (QT interval prolongation), vincristine (enhanced cardiotoxicity), and alkylating agents (enhanced hepatotoxicity) have compelled some investigators to modify the application of triazole-based prophylaxis until after the administration of cytotoxic therapy (271,272,275).

The duration of antifungal prophylaxis should be based on the duration of the host defense defect. Prevention of C/IC during the period of severe neutropenia for recipients of remission induction or reinduction therapy for acute leukemia or preengraftment period for HSCT recipients begins in parallel with the administration of the cytotoxic regimen and ends with sustained recovery of the ANC to at least 0.5×10⁹/L (266). HSCT recipients often begin prophylaxis with conditioning therapy and end with recovery of the ANC to at least 0.5×10⁹/L (263,264), despite the dearth of evidence supporting this practice (264,276). There has been no consensus regarding the duration of antifungal prophylaxis in allogeneic HSCT recipients. The start date has varied from the beginning of conditioning therapy (263,275) to the day of (277) or day after (278) transplant. The reported stop dates have also varied significantly and include the time of recovery of the ANC to at least 0.5×10⁹/L (263), a finite protocol-driven post-transplant day (day 75 [277], day 100 [278], day 120 [275] or day 180 [275]), or until cessation of immunosuppressive therapy (263). Based on the observed overall survival advantage for the administration of antifungal prophylaxis beyond engraftment (279), it seems prudent to recommend the duration of prophylaxis until at least day 75 post-transplant. The antifungal effects of mould-active agents such as itraconazole (275), posaconazole (271,272), voriconazole (269) and micafungin (273) are very similar to fluconazole.

Several systematic reviews (267,268,280-284) evaluating the published clinical trials of antifungal prophylaxis efficacy are available for review. These studies have demonstrated clinically important reductions by approximately 50% in a variety of outcomes including the use of empirical antifungal therapy for persistent neutropenic fever (OR 0.52, 95% CI 0.42 to 0.67 for fluconazole compared with placebo or no treatment [267]; RR 0.83, 95% CI 0.73 to 0.88 for systemic antifungals including fluconazole, itraconazole, ketoconazole or parenteral amphotericin B compared with placebo, no treatment or oral polyenes [284]), mucosal colonization, superficial fungal infection (OR 0.54; 95% CI 0.44 to 0.74), proven IFI (OR 0.50, 95% CI 0.41 to 0.61 [284]), IFI-related mortality (OR 0.48, 95% CI 0.28 to 0.81 [267]; RR 0.49, 95% CI 0.23 to 0.75 [284]), and all-cause mortality (OR 0.76, 95% CI 0.62 to 0.95 [267]; RR 0.49, 95% CI 0.32 to 0.75 [284]). Prophylaxis-related reduction of all-cause mortality is demonstrable in subsets of patients with prolonged severe neutropenia (ANC less than 0.5×10⁹/L for more than 15 days) such as acute leukemia patients undergoing intensive induction therapy or those undergoing allogeneic HSCT (267,284). Moreover, the protective effects against C/IC are more apparent when event rates are greater than 15% (280) (RR 0.31, 95% CI 0.23 to 0.41 [284]). Similar effects are also noted for patients with non-albicans Candida infection (RR 0.46, 95% CI 0.31 to 0.47) (284). Event rates for proven C/IC among neutropenic patients not receiving systemic antifungal prophylaxis have ranged from 3% to 15% (267,280). Fluconazole, itraconazole, posaconazole and caspofungin or micafungin have reduced the reported event rates to ranges of 0.4% to 12% (267,268,271,272), 0.5% to 7% (267,268,271,272), 0.7% to 2.3% (271,272) and 0% to 2% (273,274), respectively. Fluconazole chemoprophylaxis has been associated with reductions in all-cause mortality among allogeneic HSCT recipients (267,279,285), but not autologous HSCT (276,286) or acute leukemia patients unless the neutropenic period lasted longer than 14 days (267).

**Prevention of C/IC in solid organ transplant recipients**

**Recommendations (Table 7)**

5. Hepatic transplantation
   i. Data are insufficient to support routine fungal cultures of the donor duodenal fluid (C-III); and
   ii. For transplant recipients at high risk, as described in the text below, fluconazole 400 mg/day for four weeks post-transplant may be recommended (A-I); and
   iii. Data are insufficient to support a recommendation for extended-spectrum azoles (posaconazole or voriconazole) or the echinocandins for this indication (C-III).

6. Pancreatic transplantation
   i. Data are insufficient to support routine fungal cultures of the donor duodenal fluid (C-III); and
   ii. To support anastomotic healing, fluconazole 400 mg/day for four weeks post-transplant may be recommended (B-III). Alternative antifungal agents for this purpose may include lipid formulations of amphotericin B, extended-spectrum azoles or echinocandins (B-III).

7. Small bowel transplantation
   i. For centres where C albicans is prevalent, fluconazole 400 mg/day for four weeks post-transplant may be recommended (B-III). In centres where C glabrata and C krusei are potentially more prevalent, a lipid formulation of amphotericin B 3 mg/kg/day to 5 mg/kg/day may be substituted (B-III).

8. Renal transplantation:
   i. Data are insufficient to support a recommendation for routine antifungal prophylaxis (C-III).
### Table 7
Recommendations for the prophylaxis and treatment of candidemia/invasive candidiasis (C/IC) in non-neutropenic patients

<table>
<thead>
<tr>
<th>Therapeutic strategy</th>
<th>Preferred</th>
<th>Antifungal therapeutic options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prophylactic therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic transplantation</td>
<td>Not routinely recommended. High-risk groups: Fluconazole 400 mg/day for 4 weeks post-transplant (A-I)</td>
<td>Insufficient data to recommend ESA or ECH (C-III)</td>
</tr>
<tr>
<td>Pancreas transplantation</td>
<td>Fluconazole 400 mg/day for 4 weeks post-transplant (B-II)</td>
<td>IV LFAmB 3 mg/kg/day, or ESA (oral itraconazole 200 mg twice a day, oral posaconzole 200 mg three times a day, or oral voriconazole 200 mg twice a day) or ECH (IV micafungin 50 mg/day or IV caspofungin 50 mg/day) (B-III)</td>
</tr>
<tr>
<td>Small bowel transplantation</td>
<td>Fluconazole 400 mg/day for 4 weeks post-transplant where Candida albicans is prevalent (B-III)</td>
<td>LFAmB 3 mg/kg/day where Candida glabrata and Candida krusei are potentially more prevalent (B-III)</td>
</tr>
<tr>
<td>Renal transplantation</td>
<td>Insufficient data to support a recommendation for anti-Candida prophylaxis (C-III)</td>
<td>NA</td>
</tr>
<tr>
<td>Heart/lung transplantation</td>
<td>Specific recommendation for anti-Candida prophylaxis cannot be made (B-III). Higher-risk patients (see text) may benefit from anti-Candida prophylaxis with IV/oral fluconazole 400 mg daily (A-I)</td>
<td>NA</td>
</tr>
<tr>
<td>Intensive care unit</td>
<td>Anti-Candida prophylaxis is not recommended (B-III)</td>
<td>NA</td>
</tr>
<tr>
<td>Severe acute pancreatitis</td>
<td>Insufficient data to support a recommendation for anti-Candida prophylaxis (C-III)</td>
<td>NA</td>
</tr>
<tr>
<td>Pre-emptive therapy</td>
<td>Not recommended – insufficient data (C-III)</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Empirical therapy in intensive care unit patients based on prediction rules</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemodynamically stable</td>
<td>IV fluconazole 800 mg → IV/oral 400 mg daily (B-II)</td>
<td>NA</td>
</tr>
<tr>
<td>Hemodynamically unstable</td>
<td>IV ECH (IV anidulafungin 200 mg → 100 mg daily; or IV caspofungin 70 mg → 50 mg daily; or IV micafungin 100 mg daily) (C-III)</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Treatment of documented C/IC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemodynamically stable and no previous azole exposure</td>
<td>Fluconazole 800 mg → IV/oral 400 mg daily (A-I); or IV ECH (IV anidulafungin 200 mg → 100 mg daily; or IV caspofungin 70 mg → 50 mg daily; or IV micafungin 100 mg daily) (A-I)</td>
<td>IV AmB-d 0.5 mg/kg/day to 1.0 mg/kg/day (B-I); or IV LFAmB 3 mg/kg/day (B-I)</td>
</tr>
<tr>
<td>Hemodynamically unstable and/or previous azole exposure</td>
<td>IV ECH (IV anidulafungin 200 mg → 100 mg daily; or IV caspofungin 70 mg → 50 mg daily; or IV micafungin 100 mg daily) (B-III), except Candida parapsilosis where fluconazole 800 mg → IV/oral 400 mg is used daily (B-II)</td>
<td>IV LFAmB 3 mg/kg/day (C-II) or IV AmB-d 0.5 mg/kg/day to 1.0 mg/kg/day (C-II)</td>
</tr>
<tr>
<td>Urinary tract infection (400,401)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cystitis</td>
<td>IV/oral fluconazole 200 mg daily for 2 weeks (A-II)</td>
<td>IV AmB-d 0.3 mg/kg/day to 0.6 mg/kg/day for 7–10 days (B-II)</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>IV/oral fluconazole 200 mg to 400 mg daily for 2 weeks (B-II)</td>
<td>IV AmB-d 0.5 mg/kg/day to 1.0 mg/kg/day for 2 weeks (C-III)</td>
</tr>
<tr>
<td>Urinary fungus ball</td>
<td>IV/oral fluconazole 200 mg to 400 mg daily or IV AmB-d 0.5 mg/kg/day to 1.0 mg/kg/day for at least 2 weeks (C-III)</td>
<td>AmB-d local irrigation (C-II)</td>
</tr>
<tr>
<td>Central nervous system candidiasis (402-404)</td>
<td>IV AmB-d 0.5 mg/kg/day to 1.0 mg/kg/day or IV LFAmB 3 mg/kg/day to 5 mg/kg/day (B-II)</td>
<td>Fluconazole 400 mg to 800 mg (IV/oral) daily (C-III)</td>
</tr>
<tr>
<td>Endophthalmitis (405,406)</td>
<td>IV AmB-d 0.6 mg/kg/day to 1.0 mg/kg/day or IV/oral fluconazole 400 mg to 800 mg daily (B-II)</td>
<td>IV LFAmB 3 mg/kg/day to 5 mg/kg/day, intravitreal injection of AmB-d (C-III)</td>
</tr>
<tr>
<td>Septic arthritis (407,408)</td>
<td>IV AmB-d 0.6 mg/kg/day to 1.0 mg/kg/day or IV/oral fluconazole 400 mg daily for 6 weeks (C-III)</td>
<td>IV LFAmB 3 mg/kg/day to 5 mg/kg/day (C-III)</td>
</tr>
<tr>
<td>Osteomyelitis (409)</td>
<td>IV AmB-d 0.6 mg/kg/day to 1.0 mg/kg/day, or IV LFAmB 3 mg/kg/day to 5 mg/kg/day initially then fluconazole 400 mg daily for 6–12 months (C-III)</td>
<td>ECH (IV micafungin 50 mg/day or IV caspofungin 50 mg/day) then fluconazole for 6–12 months (C-III)</td>
</tr>
<tr>
<td>Endocarditis (410)</td>
<td>IV AmB-d 0.6 mg/kg/day to 1.0 mg/kg/day, or IV LFAmB 3 mg/kg/day to 5 mg/kg/day or ECH (IV micafungin 50 mg/day or IV caspofungin 50 mg/day) (B-III)</td>
<td>Fluconazole 400 mg to 800 mg daily after stabilization and surgical intervention (C-III)</td>
</tr>
<tr>
<td>Septic thrombophlebitis (411)</td>
<td>IV/oral fluconazole 400 mg daily or IV ECH daily (anidulafungin 200 mg → 100 mg, or caspofungin 70 mg → 50 mg, or micafungin 100 mg) with surgical excision of vein for 2 weeks after negative blood cultures (C-III)</td>
<td>IV AmB-d 0.5 mg/kg/day to 1.0 mg/kg/day or IV LFAmB 3 mg/kg/day to 5 mg/kg/day (C-III)</td>
</tr>
</tbody>
</table>

AmB-d Amphotericin B deoxycholate; ECH Echinocandins; ESA Extended-spectrum azoles; IV Intravenous; LFAmB Lipid formulation amphotericin B; NA Not applicable
9. Lung and heart/lung transplantation
- Specific recommendations for anti-Candida prophylaxis cannot be made in isolation. The risks for invasive aspergillosis must be considered when deciding on prophylaxis.

10. Cardiac transplantation
- Specific recommendations for anti-Candida prophylaxis cannot be made in isolation. The risks for invasive aspergillosis must be considered.

Summary of evidence
IFI in solid organ transplantation (SOT) remains a significant problem and the three major determinants of these infections are the complexity of the transplant surgery, environmental exposures and net state of immunosuppression (287). This interplay results in three definable risk periods for disease: early (first month after transplantation), intermediate (one to six months post-transplant), and late (beyond six months) (288). Candida species are the most common pathogens associated with IFI in SOT (289) and occur predominantly during the early period and during the early portion of the intermediate period (288). The risk for C/IC may be influenced by several factors including gastrointestinal colonization from the environment, the intensity of immunosuppressive therapy and the type of transplant. C/IC is more common among liver, pancreas and bowel allografts ostensibly attributable to the technical complexities and complications of the surgical procedures involving transection of the gastrointestinal mucosa with the potential of subsequent dissemination of endoluminal Candida species. Because the incidence and outcomes vary with the organ transplanted, the need for, as well as the impact of, antifungal chemoprophylaxis in SOT patients varies widely.

The overall baseline event rate for IFI in hepatic transplantation has been reported to be 14.1% (95% CI 10.7% to 18.2%). Two systematic reviews (290,291) of the prophylaxis efficacy of fluconazole, itraconazole and liposomal amphotericin B have demonstrated that antifungal prophylaxis does reduce the rates of proven IFI (RR 0.33 to 0.39, 95% CI 0.18 to 0.59 to 0.85; number needed to treat [NNT] is between 12 and 14), the majority of which are C/IC, among liver transplant recipients. The effects were most pronounced for patients receiving fluconazole in doses of at least 400 mg daily (RR 0.24, 95% CI 0.10 to 0.57) for more than four weeks (RR 0.25, 95% CI 0.11 to 0.56) (291). Despite a 70% reduction in fungal infection-related mortality (RR 0.30, 95% CI 0.12 to 0.75) (290), prophylaxis had no impact on all-cause mortality compared with controls (RR 0.84, 95% CI 0.54 to 1.30) (291). However, prophylaxis is associated with almost a 40% increased risk for drug-related adverse effects (RR 1.38, 95% CI 1.04 to 1.83) (290). Moreover, the administration of empirical antifungal therapy for suspected IFI was not reduced by prophylaxis (RR 0.80, 95% CI 0.39 to 1.67) (290). Given these observations, routine administration of antifungal prophylaxis to all liver transplant recipients does not seem warranted. Prophylaxis should be considered for patients at high risk (25%) for C/IC, defined by two or more of the following: fulminant hepatitis, preoperative administration of corticosteroids, dialysis or renal failure, or postoperative bacterial or cytomegalovirus infection. Under such conditions, the NNT to prevent one case of IC is 6, which is low (292). It may be recommended that such patients receive prophylaxis with a daily dose of 400 mg of fluconazole for at least four weeks from the time of transplant. Under circumstances in which invasive aspergillosis is a risk, oral itraconazole in a daily dose of greater than 200 mg may be an alternative (268). Other extended-spectrum azoles (voriconazole or posaconazole) or the echinocandins (micafungin or anidulafungin) have not been studied under these circumstances, and cannot be recommended for routine prophylaxis in liver transplantation. Caspofungin prophylaxis for high-risk liver transplant recipients has been demonstrated to be effective in an open-label noncomparative trial (293).

The reported incidence of IFI in pancreatic transplantation, almost all due to Candida species (294,295), ranges from 6% to 38% (289,296). Pancreatic transplantation is performed as a single procedure (pancreas transplant alone) or as a combined procedure concurrently with (simultaneous pancreas kidney) or after (pancreas after renal) renal transplantation. The risk for C/IC during the post-transplantation period is linked to the pancreatic allograft procedure, wherein a segment of the donor duodenum containing the pancreatic duct is involved in the transplant. Donor duodenal fungal cultures were predictive of subsequent intra-abdominal infection in one study (297), but not in others (298,299). Accordingly, such cultures are not recommended. The risks for post-transplant IFI include enteric drainage, vascular graft thrombosis and postperfusion pancreatitis. Until anastomotic healing can occur, antifungal prophylaxis with fluconazole (400 mg/day) given over at least a four-week period has been recommended (289) based on retrospective observational evidence (295). Other observational studies (297,300-302) using fluconazole prophylaxis regimens have been inconsistent in reporting outcome data. The American Society of Transplantation recommends that fluconazole prophylaxis (400 mg daily) be administered for at least four weeks after transplant, with duration dependent on control of other risk factors for infection. Alternatively, lipid formulation amphotericin B, caspofungin or newer extended-spectrum azoles may be used (288).

Transplantation of the small bowel may be performed as a single procedure or as a combined multivisceral procedure with the liver or in combination with the liver and other organs including stomach, pancreas, duodenum or kidney. The reported IFI rates after this type of transplant have been high, ranging from 28% to 59%, approximately 90% of which are due to Candida species (289,296). Risk factors for IFI in this group of patients include graft rejection or dysfunction, augmented immunosuppression, anastomotic disruption and multivisceral transplantation (289). Although there are no randomized controlled trials or even case-control studies of antifungal prophylaxis in intestinal transplant, it seems prudent, in the presence of the risk factors cited above, to recommend prophylaxis (fluconazole 400 mg daily or where non-albicans Candida species are prevalent, a lipid formulation of amphotericin B 3 mg/kg/day to 5 mg/kg/day) for a period of at least four weeks to allow anastomotic healing in the absence of graft rejection (289).

Renal transplantation is infrequently associated with fungal infection (289,296). IFI rates of 1% to 14% have been reported (296,303,304). Candida species are isolated in most cases (70% to 80%) within the first three to six months post-transplant (304-307). The majority of Candida species infections that
TABLE 8 Prediction rules for the diagnosis of candidemia/invasive candidiasis in the intensive care unit (ICU)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study population</th>
<th>Risk factors for candidemia/invasive candidiasis</th>
<th>Risk score</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>412</td>
<td>1107 non-neutropenic adult patients in 36 ICUs &gt;7 days in Spain, Argentina and France. (1-3)-b-D-glucan and anti-Candida antibodies once weekly for 4 weeks</td>
<td>Candida score&lt;br&gt;Upper gastrointestinal antibodies&lt;br&gt;Severe sepsis&lt;br&gt;(1-3)-b-D-glucan&lt;br&gt;Anti-Candida antibodies once weekly for 4 weeks</td>
<td>1&lt;br&gt;1&lt;br&gt;1&lt;br&gt;2&lt;br&gt;≥75 pg/mL</td>
<td>Invasive candidiasis&lt;br&gt;improbable with score &lt;3&lt;br&gt;independent predictor of invasive candidiasis and higher response to empirical antifungal therapy</td>
</tr>
<tr>
<td>242</td>
<td>221 surgical ICU patients with peritonitis</td>
<td>Female sex&lt;br&gt;Upper gastrointestinal origin of peritonitis&lt;br&gt;Intraoperative cardiovascular failure&lt;br&gt;Previous antimicrobial therapy ≥48 h before onset of peritonitis</td>
<td>N/A</td>
<td>Presence of 3 risk factors related to Candida peritonitis; accuracy 71%</td>
</tr>
<tr>
<td>243</td>
<td>2690 medical-surgical ICU patients admitted &gt;4 days in USA and ≥4 days in USA and Brazil</td>
<td>Patients in ICU &gt;4 days, any systemic antibiotic (days 1 to 3) or central venous catheter (days 1 to 3) and at least 2 of the following:&lt;br&gt;Total parenteral nutrition (days 1 to 3)&lt;br&gt;Any dialysis (days 1 to 3)&lt;br&gt;Any major surgery (days —7 to 0)&lt;br&gt;Pancreatitis (days —7 to 0)&lt;br&gt;Any use of steroids (days —7 to 3)&lt;br&gt;Use of immunosuppressive agents (days —7 to 0)</td>
<td>N/A</td>
<td>RR 4.36, sensitivity 34%, specificity 90%</td>
</tr>
</tbody>
</table>

N/A Not applicable

occur involve superficial mucosal surfaces of the oropharynx, esophagus or urogenital tissues. Given the low incidence of invasive Candida species infection in renal allograft recipients, routine antifungal prophylaxis is not recommended (308).

The reported incidence of IFI among lung and lung-heart transplant recipients is in the range of 15% to 44%, of which 4% to 72% and 25% to 50% may be due to Candida species and Aspergillus species, respectively (296). As for nontransplant patients (1), the simple isolation of Candida species from respiratory secretions of lung transplant recipients is not considered to be an indication for treatment (309,310). While Candida species may, on occasion, be responsible for lower respiratory tract infection post-transplant (311), studies have focused on chemoprophylaxis strategies for preventing invasive aspergillosis, which in parallel reduce the incidence of C/IC. Accordingly, there are no specific recommendations for antifungal prophylaxis against Candida species in lung transplant recipients independent of those targeting Aspergillus species (refer to upcoming AMMI Canada Clinical Practice Guidelines on Aspergillus species).

The reported incidence of IFI among cardiac transplants is in the range of 5% to 21%, with the majority (70% to 90%) being due to Aspergillus species (296). The incidence of C/IC in cardiac transplantation without simultaneous lung allograft is very low – less than 1% (308). That no studies on antifungal prophylaxis targeting Candida species could be identified is consistent with this observation. Accordingly, there are no specific recommendations for routine anti-Candida prophylaxis in this patient population.

Prevention of C/IC in ICU patients

Recommendations (Table 7)

11. Routine antifungal prophylaxis of all ICU patients is not recommended (B-III). However, antifungal prophylaxis aimed at Candida species using fluconazole in selected high-risk subgroups of ICU patients may significantly decrease the likelihood of developing proven C/IC and reduce all-cause mortality (A-I).

12. High-risk subgroups of patients who may be candidates for prophylaxis include the following:

i. ICU patients with recurrent gastrointestinal perforation or anastomotic leakage. In this selected high-risk group, IV fluconazole 400 mg once daily may be administered until either complete resolution of intra-abdominal disease, development of proven Candida species infection requiring directed antifungal therapy, or development of a severe drug-related adverse event (A-I);

ii. Patients admitted to a tertiary referral centre ICU (surgical or medical) with a baseline risk for C/IC of 10% or greater if there is an anticipated stay of more than three days (Table 8). In such cases, oral fluconazole 400 mg daily may be administered until ICU discharge, until initiation of directed antifungal therapy for suspected/confirmed disease or development of a severe drug-related adverse event (A-I); and

iii. There are insufficient data to support specific recommendations for antifungal prophylaxis in SAP (C-III).

Summary of evidence

Patients admitted to the ICU represent another population at risk for C/IC. Among those ICU patients without neutropenia, Candida species represent the overwhelming majority (greater than 80%) of such infections (312,313), with attributable mortality rates of 24% to 49% and excess ICU stays of 12.7 days (55,314-316). While most of the experience has emerged from observations in surgical ICU patients, data suggest that medical ICU patients are also significantly affected by invasive Candida species infection (233,317). Hence, there is a need for preventive measures for both types of ICU patients.

The overall incidence of C/IC in the critical care setting is relatively low (0.5% to 2%), yet the crude mortality often ranges from one in four patients to more than one in two patients
Invasive candidiasis treatment guidelines

1. Pre-emptive use of antifungal agents for C/IC in neutropenic patients based on the presence of colonization and/or surrogate serological markers for C/IC is impractical and not recommended (C-III).

2. Empirical antifungal therapy is recommended for patients with a persistent or recrudescence neutropenic fever syndrome after four to seven days of broad-spectrum antibacterial therapy without a focus of infection for suspected C/IC or other possible IFI (B-I).

3. Therapeutic choices for empirical antifungal therapy in febrile neutropenic cancer patients and HSCT recipients with a persistent or recrudescence neutropenic fever syndrome include a lipid formulation of IV amphotericin B at a dose of 3 mg/kg/day (A-I), IV caspofungin 70 mg as a loading dose and then IV 50 mg daily (A-I), IV voriconazole 6 mg/kg/day to 1.0 mg/kg/day (B-II in the absence of risk factors for nephrotoxicity, otherwise the deoxycholate formulation of amphotericin B is not recommended), fluconazole for those less critically ill patients with neutropenia of short duration (seven days or fewer) and in the absence of azole prophylaxis with IV 800 mg as a loading dose and then IV 400 mg daily with the option of proceeding to oral doses of 400 mg daily (B-II), and IV voriconazole 6 mg/kg every 12 h for 24 h and then IV 4 mg/kg every 12 h or oral doses of 200 mg twice daily (based on the risk of mould infection in these patients) (B-I).

4. The duration of empirical antifungal therapy is until resolution of symptoms and signs of infection, including fever, in conjunction with the recovery of the ANC to greater than 0.5×10⁹/L for at least 48 h (A-I).

5. For microbiologically or histologically documented (proven) C/IC in neutropenic patients and HSCT recipients, IV amphotericin B deoxycholate 0.6 mg/kg/day to 1.0 mg/kg/day (in the absence of risk factors for nephrotoxicity), a lipid formulation of IV amphotericin B 3 mg/kg/day, and IV caspofungin 70 mg as a loading dose and then IV 50 mg daily are all recommended (A-I). IV anidulafungin 200 mg initially followed by IV 100 mg daily or IV micafungin 100 mg daily may also be effective (B-III). Fluconazole 800 mg followed by IV/oral doses of 400 mg may be used in hemodynamically stable, less severely ill patients with neutropenia of shorter duration (seven days or fewer) (A-II). Choice of agent will depend on local concurrence of other established risk factors for C/IC including prolonged use of indwelling catheters and administration of total parenteral nutrition (330). Candida species may be recovered from patients with SAP either as a single isolate or with other enteric bacteria at the time of the primary or subsequent debridement and is often associated with excess mortality (327,331-336). It is estimated from retrospective series that the incidence of C/IC in SAP may be 5% to 15% (327). However, there is no consensus case definition for C/IC in SAP. While early antifungal therapy may affect mortality (328), the role of antifungal prophylaxis in SAP has been inadequately studied (336,337).

6. Treatment of C/IC in neutropenic patients and HSCT recipients

Recommendations (Table 6)

13. Pre-emptive use of antifungal agents for C/IC in neutropenic patients based on the presence of colonization and/or surrogate serological markers for C/IC is impractical and not recommended (C-III).

14. Empirical antifungal therapy is recommended for patients with a persistent or recrudescence neutropenic fever syndrome after four to seven days of broad-spectrum antibacterial therapy without a focus of infection for suspected C/IC or other possible IFI (B-I).

15. Therapeutic choices for empirical antifungal therapy in febrile neutropenic cancer patients and HSCT recipients with a persistent or recrudescence neutropenic fever syndrome include a lipid formulation of IV amphotericin B at a dose of 3 mg/kg/day (A-I), IV caspofungin 70 mg as a loading dose and then IV 50 mg daily (A-I), IV voriconazole 6 mg/kg/day to 1.0 mg/kg/day (B-II in the absence of risk factors for nephrotoxicity, otherwise the deoxycholate formulation of amphotericin B is not recommended), fluconazole for those less critically ill patients with neutropenia of short duration (seven days or fewer) and in the absence of azole prophylaxis with IV 800 mg as a loading dose and then IV 400 mg daily with the option of proceeding to oral doses of 400 mg daily (B-II), and IV voriconazole 6 mg/kg every 12 h for 24 h and then IV 4 mg/kg every 12 h or oral doses of 200 mg twice daily (based on the risk of mould infection in these patients) (B-I).

16. The duration of empirical antifungal therapy is until resolution of symptoms and signs of infection, including fever, in conjunction with the recovery of the ANC to greater than 0.5×10⁹/L for at least 48 h (A-I).

17. For microbiologically or histologically documented (proven) C/IC in neutropenic patients and HSCT recipients, IV amphotericin B deoxycholate 0.6 mg/kg/day to 1.0 mg/kg/day (in the absence of risk factors for nephrotoxicity), a lipid formulation of IV amphotericin B 3 mg/kg/day, and IV caspofungin 70 mg as a loading dose and then IV 50 mg daily are all recommended (A-I). IV anidulafungin 200 mg initially followed by IV 100 mg daily or IV micafungin 100 mg daily may also be effective (B-III). Fluconazole 800 mg followed by IV/oral doses of 400 mg may be used in hemodynamically stable, less severely ill patients with neutropenia of shorter duration (seven days or fewer) (A-II). Choice of agent will depend on local concurrence of other established risk factors for C/IC including prolonged use of indwelling catheters and administration of total parenteral nutrition (330). Candida species may be recovered from patients with SAP either as a single isolate or with other enteric bacteria at the time of the primary or subsequent debridement and is often associated with excess mortality (327,331-336). It is estimated from retrospective series that the incidence of C/IC in SAP may be 5% to 15% (327). However, there is no consensus case definition for C/IC in SAP. While early antifungal therapy may affect mortality (328), the role of antifungal prophylaxis in SAP has been inadequately studied (336,337).

7. Treatment of C/IC in neutropenic patients and HSCT recipients

Recommendations (Table 6)

13. Pre-emptive use of antifungal agents for C/IC in neutropenic patients based on the presence of colonization and/or surrogate serological markers for C/IC is impractical and not recommended (C-III).

14. Empirical antifungal therapy is recommended for patients with a persistent or recrudescence neutropenic fever syndrome after four to seven days of broad-spectrum antibacterial therapy without a focus of infection for suspected C/IC or other possible IFI (B-I).

15. Therapeutic choices for empirical antifungal therapy in febrile neutropenic cancer patients and HSCT recipients with a persistent or recrudescence neutropenic fever syndrome include a lipid formulation of IV amphotericin B at a dose of 3 mg/kg/day (A-I), IV caspofungin 70 mg as a loading dose and then IV 50 mg daily (A-I), IV amphotericin B deoxycholate 0.6 mg/kg/day to 1.0 mg/kg/day (B-II in the absence of risk factors for nephrotoxicity, otherwise the deoxycholate formulation of amphotericin B is not recommended), fluconazole for those less critically ill patients with neutropenia of short duration (seven days or fewer) and in the absence of azole prophylaxis with IV 800 mg as a loading dose and then IV 400 mg daily with the option of proceeding to oral doses of 400 mg daily (B-II), and IV voriconazole 6 mg/kg every 12 h for 24 h and then IV 4 mg/kg every 12 h or oral doses of 200 mg twice daily (based on the risk of mould infection in these patients) (B-I).

16. The duration of empirical antifungal therapy is until resolution of symptoms and signs of infection, including fever, in conjunction with the recovery of the ANC to greater than 0.5×10⁹/L for at least 48 h (A-I).

17. For microbiologically or histologically documented (proven) C/IC in neutropenic patients and HSCT recipients, IV amphotericin B deoxycholate 0.6 mg/kg/day to 1.0 mg/kg/day (in the absence of risk factors for nephrotoxicity), a lipid formulation of IV amphotericin B 3 mg/kg/day, and IV caspofungin 70 mg as a loading dose and then IV 50 mg daily are all recommended (A-I). IV anidulafungin 200 mg initially followed by IV 100 mg daily or IV micafungin 100 mg daily may also be effective (B-III). Fluconazole 800 mg followed by IV/oral doses of 400 mg may be used in hemodynamically stable, less severely ill patients with neutropenia of shorter duration (seven days or fewer) (A-II). Choice of agent will depend on local concurrence of other established risk factors for C/IC including prolonged use of indwelling catheters and administration of total parenteral nutrition (330). Candida species may be recovered from patients with SAP either as a single isolate or with other enteric bacteria at the time of the primary or subsequent debridement and is often associated with excess mortality (327,331-336). It is estimated from retrospective series that the incidence of C/IC in SAP may be 5% to 15% (327). However, there is no consensus case definition for C/IC in SAP. While early antifungal therapy may affect mortality (328), the role of antifungal prophylaxis in SAP has been inadequately studied (336,337).
epidemiology, use of azole antifungal prophylaxis and concerns about coexistent mould infection.

18. If *C. parapsilosis* C/IC is present and caspofungin, anidulafungin or micafungin has been used, another agent of a different class (amphotericin B deoxycholate, lipid formulation of amphotericin B or fluconazole for less critically ill patients with a shorter duration of neutropenia) may be considered if the patient is not responding or improving. However, if the patient has improved on echinocandin therapy, then it may be continued (B-III). For hemodynamically unstable neutropenic patients and HSCT recipients with proven *C. parapsilosis* C/IC, amphotericin B deoxycholate or a lipid formulation of amphotericin B is preferred (B-III).

19. Removal of venous access devices is recommended for candidemia in neutropenic cancer patients and HSCT recipients (whether catheter related or not), provided that this procedure is feasible (B-II).

20. The duration of therapy for microbiologically documented C/IC in neutropenic patients is at least two weeks after the clearance of organisms from the bloodstream and/or the infected body site with resolution of all signs and symptoms at the infected site and recovery of the ANC to greater than 0.5×10^9/L for at least 48 h (A-I).

**Summary of evidence**

The risk of invasive *Candida* infections is highest in patients with hematological malignancy, particularly acute leukemia and HSCT recipients who are rendered neutropenic by antineoplastic chemotherapy (47,338). Prevention of C/IC in neutropenic patients and HSCT by means of antifungal prophylaxis has been described above. The pre-emptive antifungal strategy in neutropenic patients is still in the process of development. The precise definition remains controversial. It has been explored in presumed invasive aspergillosis with the use of galactomannan and computed tomography scanning of the chest, acting as surrogate markers indicative of the IFI (339). Moreover, a recent randomized clinical trial (340), comparing a pre-emptive strategy based on the presence of fever and positive galactomannan versus empirical antifungal therapy for fever with negative surrogate markers and using polynucleic, found a reduction in antifungal drug costs for pre-emptive therapy but lower survival rates for patients receiving induction chemotherapy. However, evidence for the use of surrogate serological markers for *Candida* as a guide to the initiation of pre-emptive antifungal therapy in neutropenic patients has been less forthcoming (refer to the section on Diagnosis of C/IC). Thus, pre-emptive therapy for C/IC in neutropenic patients may be premature in Canada due to the lack of availability and limitations for (1,3)-β-D-glucan serological testing.

Empirical antifungal therapy for suspected *Candida* infection in patients with persistent or recrudescent neutropenic fevers of unknown origin despite four to seven days of broad-spectrum antibacterial therapy is a well-established practice (341). Pioneering work by Pizzo et al (258) with concomitant by the European Organization for Research and Treatment of Cancer (EORTC) (342) have provided evidence for this approach. This practice reduces morbidity associated with documented IFIs (fewer IFIs) and febrile morbidity, but has not had a major impact on survival (343,344). Agents used for this purpose have included amphotericin B deoxycholate (258,259,345), liposomal amphotericin B (345), amphotericin B lipid complex (342), fluconazole (346,347), itraconazole (348) and caspofungin (349). The panel, similar to other guideline panels (7,9,341), recognizes the use of voriconazole for this indication, despite the statistical controversies surrounding the original trial (350,351). Guidelines describing the time of initiation and duration for empirical antifungal therapy have been produced by the Infectious Diseases Society of America (IDSA) (344) and the National Comprehensive Cancer Network (NCCN) (11). However, the agent of choice for empirical antifungal therapy has not been resolved and depends on the following: local epidemiology of IFIs in a particular institution; patient factors such as renal function, concomitant drugs, patient tolerance of medications and allergies; cost of the antifungal medication; and the need to provide adequate coverage for mould pathogens.

Therapy for microbiologically or histologically documented (proven) C/IC in neutropenic hematological cancer patients and HSCT recipients has only been partially addressed in the randomized empirical antifungal therapy clinical trials of amphotericin B deoxycholate versus liposomal amphotericin B (345), and caspofungin versus liposomal amphotericin B (349). Response rates for neutropenic candidemic patients are lower than their non-neutropenic counterparts (352). Based on these clinical trials, it appears that liposomal amphotericin B achieved a slightly better success rate against infections (that included candidiasis) diagnosed at the initiation of therapy compared with amphotericin B deoxycholate (81.8% versus 72.7%) (345). Similarly, caspofungin achieved slightly better responses in the treatment of baseline *Candida* infections compared with liposomal amphotericin B (66.7% versus 41.7%) (349). Moreover, Mora-Duarte et al (158) demonstrated that there was a nonsignificant difference between caspofungin and amphotericin B deoxycholate (50% versus 40%) for the treatment of C/IC in their neutropenic patients. Furthermore, other investigators have corroborated the success rate of caspofungin for candidemia (68%) in neutropenic patients (353). However, any echinocandin-related treatment advantage in candidemic patients may be offset by the confounding effect of severe neutropenia. A systematic review (352) noted that the apparent advantage of echinocandin therapy over amphotericin B may be confined to those patients who were not neutropenic at baseline compared with those who were indeed neutropenic at the onset of candidemia. In addition, it would appear that *C. parapsilosis* may be less responsive to the echinocandins (158).

Fluconazole has also been effective (346,347,354). There does not appear to be any decisive advantage of one agent over another for C/IC in neutropenic patients, but the numbers are limited. Rather, the selection of the antifungal agent is predicated on the local epidemiology of the fungal isolates, the susceptibility of the isolates, the degree of immunosuppression and the possibility of the presence of coexistent mould infection that may necessitate the use of specific therapies. Thus, fluconazole is deemed inappropriate in a neutropenic patient if antifungal therapy is also directed against possible coexistent mould infection. Moreover, fluconazole would also be inappropriate for neutropenic patients receiving this agent as antifungal chemoprophylaxis (6). It should also be underscored that although the efficacy of anidulafungin and micafungin for
the treatment of C/IC has been evaluated in large randomized clinical trials, there were too few neutropenic patients in both clinical trials (anidulafungin 2% [355] and micafungin 10% [356]) to come to any firm conclusions about their use in neutropenic patients. One has to consider their use in neutropenic patients based on data extrapolated from the efficacy of caspofungin (158) (13% of 109 patients) for the treatment of C/IC and the treatment of baseline fungemia when it was used empirically (349), as well as the merits of the echinocandin class to treat C/IC effectively.

The duration of therapy for suspected and proven C/IC in neutropenic patients depends on clearance of the pathogens from the bloodstream, resolution of signs and symptoms of infection for at least 48 h, and the resolution of neutropenia with a rise in ANC to greater than 0.5×10⁹/L for more than 48 h. This therapy must be continued for at least 14 days beyond the clearance of organisms from the bloodstream (6). Venous access device removal has been associated with more rapid resolution of candidemia and is, therefore, advocated (4,256,356,357). However, there may be occasions when venous access catheter removal is impossible or ill advised (eg, extremely limited access or severe thrombocytopenia). In such situations, administration of the antifungal agent should be alternated among the catheter lumens daily.

In addition, further comments are warranted for the treatment of chronic disseminated hepatosplenic candidiasis, a form of proven C/IC infection. Hepatosplenic candidiasis poses a unique problem in neutropenic patients. This infection arises after the dissemination of Candida organisms because of candidemia or by means of translocation from the gastrointestinal tract and transmission to the liver via the portal vein. In the liver, numerous small abscesses are formed, producing necrotizing granulomas. These abscesses with the presence of fever may only become evident with immune reconstitution as neutropenia resolves. The classical finding is multiple target lesions on radiographic imaging of the liver with an elevated alkaline phosphatase level (358-360). The eradication of hepatic lesions is particularly difficult and has been accomplished with fluconazole, other azoles, amphotericin B deoxycholate and lipid formulations of amphotericin B (361-363). Prolonged therapy is suggested until resolution is apparent. When the species of Candida is known to be susceptible, fluconazole is considered to be the treatment of choice (4). Some (364) have advocated the use of adjunctive oral corticosteroids (0.5 mg/kg/day to 0.8 mg/kg/day) for a mean duration of 21 days with slow reduction in dose thereafter for chronic disseminated hepatosplenic candidiasis. This has led to resolution of the hepatic lesions. However, further study is warranted before specific recommendations can be made.

Treatment of C/IC in non-neutropenic patients

Recommendations (Table 7)

21. Pre-emptive antifungal therapy in non-neutropenic patients with the presence of colonization is currently not recommended (C-III).

22. Empirical antifungal therapy may be beneficial in critically ill patients who meet specific criteria based on clinical prediction rules for C/IC (B-II). Fluconazole remains efficacious in reducing C/IC and is cost effective at a dose of 800 mg loading dose followed by IV 400 mg daily for hemodynamically stable patients (B-II). However, empirical antifungal therapy may not produce resolution of fevers of unknown origin in non-neutropenic ICU patients and is weakly endorsed (C-II). In hemodynamically unstable patients, an echinocandin (anidulafungin 200 mg initially followed by IV 100 mg daily, caspofungin 70 mg initially followed by IV 50 mg daily or IV micafungin 100 mg daily) may be preferred for empirical therapy (C-III).

23. The duration of empirical therapy in non-neutropenic patients should be 14 days (B-II).

24. For microbiologically or histologically documented (proven) C/IC in hemodynamically stable patients with no previous azole exposure in the past 30 days, fluconazole 800 mg initially followed by IV 400 mg daily, or an echinocandin (anidulafungin 200 mg as a loading dose followed by IV 100 mg daily, caspofungin 70 mg as a loading dose followed by IV 50 mg daily, or IV micafungin 100 mg daily) are recommended (A-I).

25. IV amphotericin B deoxycholate at a dose of 0.5 mg/kg/day to 1 mg/kg/day (in the absence of risk factors for nephrotoxicity) or lipid formulations of IV amphotericin B at doses 3 mg/kg/day are alternatives (B-I).

26. For proven C/IC caused by C glabrata in hemodynamically stable patients, in centres where susceptibility testing is available, fluconazole should only be used if the isolate is susceptible. However, if fluconazole is initiated at the outset but susceptibilities are not available and the patient is clinically improved, it may be continued (B-III).

27. For hemodynamically stable or unstable patients with proven C/IC caused by C parapsilosis, fluconazole is preferred (B-II). In hemodynamically unstable patients, lipid formulations of amphotericin B or amphotericin B deoxycholate are alternatives for therapy for C/IC (C-II).

28. In hemodynamically unstable patients with proven C/IC due to Candida species other than C parapsilosis with or without azole exposure, an echinocandin (anidulafungin 200 mg followed by IV 100 mg daily, caspofungin 70 mg initially followed by IV 50 mg daily or IV micafungin 100 mg daily) is preferred (B-III).

Summary of evidence

In non-neutropenic patients, C/IC infections occur most frequently in ICU and surgical patients, and those with significant comorbid illness (Table 4). The pre-emptive treatment strategy for non-neutropenic patients has not been investigated adequately. Nonculture-based diagnosis of C/IC remains elusive in non-neutropenic patients. Data have been accrued on Candida circulating antigens and antibodies (365,366), (1,3)-β-D-glucan serological testing (190,367) and polymerase chain reaction for Candida DNA (368) in critically ill patients colonized with Candida and possessing risk factors for probable or proven C/IC. Unfortunately, laboratory markers sufficiently predictive for C/IC so as to permit the institution of pre-emptive therapy have not been identified. Piarroux et al (239) attempted to assess the efficacy of pre-emptive antifungal therapy with fluconazole in preventing proven candidiasis in critically ill surgical patients. They evaluated the frequency of proven candidiasis within a specific time frame during which patients with a corrected colonization index of 0.4 or higher
were treated with fluconazole pre-emptive antifungal therapy. *Candida* infections occurred more frequently in the control cohort (7% versus 3.8%; *P*=0.03) (239). Proven C/IC decreased from 2.2% to 0%. However, in light of the absence of a readily available surrogate marker (1,3-β-D-glucan) in this study, and in Canada presently, and the paucity of efficacy data using this approach, pre-emptive therapy in non-neutropenic patients cannot be advocated at this time.

Empirical antifungal therapy in febrile non-neutropenic critically ill patients who are unresponsive to broad-spectrum antibacterial therapy has been suggested based on the predispisition of such patients to develop C/IC (369). Such an approach may have merit for the treatment of suspected *Candida* infections producing a fever of unknown origin in an ICU patient with the presence of the previously enumerated risk factors for IC, particularly in light of the poor sensitivity of current diagnostic methods (176,367,369-371). Fluconazole empirical antifungal therapy was predominantly used in the aforementioned studies at a dose of 400 mg/day. Azaouly et al (372) substantiated this approach by demonstrating the impact of colonization with *Candida* in the ICU populations. In patients with ventilator-associated pneumonia in the ICU, the presence of *Candida* species in respiratory secretions carried a poor prognosis with a greater risk of death. Moreover, a number of investigators have proposed prediction rules to direct clinicians when empirical antifungal therapy should be contemplated and initiated (240,242,243) (Table 8). In contrast, Schuster et al (373) found in their large, double-blind, placebo-controlled randomized trial for ICU patients with fever (four days or more) despite administration of broad-spectrum antibiotics and a central venous catheter in place for at least 24 h before study entry, that IV fluconazole 800 mg daily did not produce the desired resolution of fever (failure for fever to resolve in 51% of the fluconazole patients versus 57% for the placebo group). Nevertheless, documented C/IC occurred in fewer fluconazole recipients (5% versus 9% of the placebo recipients). Therefore, based on these data, it would appear at present that the concept of empirical antifungal therapy remains unsubstantiated in non-neutropenic critically ill patients. It may not resolve fever, but may mildly reduce documented C/IC.

An additional issue for consideration with regard to empirical antifungal therapy is the choice of empirical antifungal treatment for suspected C/IC. This has been assessed in an economic evaluation by Golan et al (176). IV fluconazole 800 mg as a loading dose followed by IV 400 mg daily with the option of oral therapy at a dose of 400 mg daily when the patient is clinically improved and stable appears to be endorsed most consistently (176,369). This approach may be efficacious and cost effective provided that the likelihood of C/IC is greater than 25% and the local fluconazole resistance rate is less than 24%. It should be noted that in Canada, most of the *Candida* isolates are *C* albicans and, therefore, are likely to be fluconazole susceptible (374). In addition, the duration of empirical antifungal therapy in non-neutropenic patients has not been clearly elucidated in clinical trials. Schuster et al (373) used a two-week course in their study. This time course would seem reasonable.

For microbiologically or histologically documented (proven) C/IC, therapy is predicated on two key principles. First, it is imperative to initiate therapy early. Garey et al (375) have demonstrated that delays in the time to initiation of fluconazole therapy for candidemia resulted in higher mortality rates. Initiation at day 0 had a mortality rate of 15%, while a delay in therapy initiation of one, two and three or more days resulted in mortality rates of 24%, 37% and 41%, respectively. Morrell et al (376) advanced this concept further by describing how delays in empirical antifungal therapy for candidemia until after blood cultures are positive also increases mortality. Moreover, delays in the initiation of antifungal therapy for *Candida* sepsis in the ICU are associated with decreased survival (377). The second important principle of therapy is the initiation of appropriate therapy for the pathogens causing candidemia. A multiple logistic regression analysis proved that *Candida* species infections were most often associated with inadequate therapy (378). Similarly, BSI-related mortality rates were higher for patients receiving inadequate antimicrobial therapy (37,378).

It is, therefore, suggested that non-neutropenic patients be subdivided into those who are hemodynamically stable with no recent azole exposure, thus reducing the risk of azole resistance, and those individuals who are hemodynamically unstable with or without recent azole exposure. For those patients who are hemodynamically stable and have had no antecedent azole exposure within the past 30 days, fluconazole 800 mg as a loading dose followed by IV/oral doses of 400 mg daily or an echinocandin such as IV anidulafungin 200 mg initially followed by IV 100 mg daily, IV caspofungin 70 mg as a loading dose followed by IV 50 mg daily or IV micafungin 100 mg daily are appropriate alternatives. Voriconazole offers no real potency advantage over fluconazole and presents the challenge of interpatient serum concentration variability due to genetic polymorphisms in metabolism while possessing the potential for more toxicities and drug interactions. Transition from an echinocandin to oral fluconazole for fluconazole-susceptible organisms when patients are clinically stable would seem prudent. For *C* glabrata, an echinocandin is preferred (379). Transition to fluconazole should not be undertaken unless the clinical isolate is fluconazole susceptible. If fluconazole was commenced initially for *C* glabrata C/IC and the patient has improved, such therapy may be continued. If *C* parapsilosis has produced proven C/IC, fluconazole is preferred because of the reduced activity of the echinocandins against *C* parapsilosis, although in the micafungin versus caspofungin clinical trial (356), adequate response rates were achieved with Micafungin compared with caspofungin. Once again, if the patient has improved on the echinocandin and there is a desire to continue such therapy, it is unnecessary to change it. IV amphotericin B deoxycholate 0.5 mg/kg/day to 1.0 mg/kg/day should only be considered an alternative due to its toxicities that may limit its efficacy in the treatment of C/IC. If there is intolerance or limited availability of other antifungals, amphotericin B deoxycholate and its lipid formulations (3 mg/kg/day IV) would be considered alternatives, but one must be cognizant of the side effect profile and expense of lipid formulations. As mentioned above for empirical therapy, fluconazole is still an efficacious and cost-effective agent for the treatment of C/IC. Removal of all intravenous catheters is also recommended, as previously mentioned. The duration of therapy should be two weeks after clearance of organisms from the bloodstream with the resolution of all signs and symptoms of infection. However, for disseminated disease, prolonged therapy beyond two weeks should be undertaken. Such therapy should continue until resolution of all clinical signs and symptoms.
In contrast, hemodynamically unstable patients with or without recent azole exposure should be treated with a broad-spectrum antifungal agent. An echinocandin (anidulafungin, caspofungin or micafungin) is preferred as initial therapy in these patients. Fluconazole, lipid formulations of amphotericin B and amphotericin B deoxycholate would be appropriate alternatives. However, the use of amphotericin B formulations may be limited by their toxicity, particularly in this critically ill population. In hemodynamically unstable patients with proven C. parapsilosis C/JC, fluconazole, the lipid formulations of amphotericin B or amphotericin B deoxycholate are preferred.

Additional recommendations for the treatment of other clinical infections due to Candida species are provided in Table 7.

**FUTURE DIRECTIONS**

The recent addition of new agents to the antifungal armamentarium has provided solutions for circumventing the intrinsic side effects and toxicities associated with older antifungal agents, as well as a broader spectrum of antifungal activity against emerging resistant fungal pathogens. Efficient and appropriate use of antifungal agents will only evolve from future epidemiological observations designed to refine the risk-based preventive and therapeutic use of antifungal agents in patients vulnerable to IFI. Optimal use of combinations of antifungal classes needs to be further explored. Continuous efforts aimed at the development of enhanced, accurate and rapid tests for the diagnosis of IFI will inevitably contribute to the reduction of fungal-related morbidity and mortality.

**REFERENCES**


119. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Wayne: Clinical and Laboratory Standards Institute, 2008.


Invasive candidiasis treatment guidelines


Bow et al
Bow et al


Submit your manuscripts at
http://www.hindawi.com